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FIG. 1 1 
Optical image of front surface of nDS device after anodic bonding. 
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NANOCHANNELED DEVICE AND RELATED 
METHODS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority to U.S. Provisional Patent 
Application Ser. No. 61/114,687, filed Nov. 14, 2008, entitled 
"Nanochanneled Device and Method of Use", and U.S. Pro-
visional Patent Application Ser. No. 61/168, 844, filed Apr. 
13, 2009, entitled "Nanochanneled Device and Method of 
Use", the entire disclosures of which are specifically incor-
porated herein by reference. 
This invention was made with government support under 
contract NNJ06HE06A awarded by NASA. The government 
has certain rights in this invention. 
BACKGROUND INFORMATION 
Considerable advances have been made in the field of 
therapeutic agent (e.g. drug) delivery technology over the last 
three decades, resulting in many breakthroughs in clinical 
medicine. The creation of therapeutic agent delivery devices 
that are capable of delivering therapeutic agents in controlled 
ways is still a challenge. One of the maj or requirements for an 
implantable drug delivery device is controlled release of 
therapeutic agents, ranging from small drug molecules to 
larger biological molecules. It is particularly desirable to 
achieve a continuous passive drug release profile consistent 
with zero order kinetics whereby the concentration of drug in 
the bloodstream remains constant throughout an extended 
delivery period. 
These devices have the potential to improve therapeutic 
efficacy, diminish potentially life-threatening side effects, 
improve patient compliance, minimize the intervention of 
healthcare personnel, reduce the duration of hospital stays, 
and decrease the diversion of regulated drugs to abusive uses. 
Nanochannel delivery devices may be used in drug deliv-
ery products for the effective administration of drugs. In 
addition, nanochannel delivery devices can be used in other 
applications where controlled release of a substance over time 
is needed. 
SUMMARY 
Embodiments of this invention comprise a nanochannel 
delivery device having nanochannels within a structure con-
figured to yield high mechanical strength and high flow rates. 
Various fabrication protocols may be used to form the 
nanochannel delivery device. Embodiments of the fabricated 
devices feature horizontal nanochannel lay-out (e.g., the 
nanochannel is parallel to the primary plane of the device), 
high molecule transport rate, high mechanical strength, 
optional multilayered lay-out, amenability to select channel 
lining materials, and possible transparent top cover. Based on 
silicon microfabrication technology, the dimensions of the 
nanochannel area as well as concomitant microchannel areas 
can be precisely controlled, thus providing a predictable, 
reliable, constant release rate of drug (or other) molecules 
over an extended time period. In certain embodiments, the 
nanochannel delivery device can be used to build a multilay-
ered nanochannel structure. Multilayered nanochannel struc-
tures can extend the limit of release rate range of a single layer 
nanochannel delivery device or system, and allow a wide 
range of pre-defined porosity to achieve an arbitrary release 
rate using any preferred nanochannel size. 
2 
In certain embodiments, the nanochannel delivery device 
is made of a "sandwich" of materials, composed of a thin top 
layer, the horizontal nanochannels, and a thicker bottom 
wafer. The thin top layer can house an array of microchannels 
5 that offer an inlet or outlet for diffusing molecules. It can also 
serve as the lid or ceiling for the nanochannels by providing 
the channels' top surface. The thickerbottom wafer can house 
an array of microchannels that offer a collateral outlet or inlet. 
Note that in the following, inlets are indicated in the bottom 
l0 
wafer and outlets are indicated in the top layer, but this is not 
a limit of the invention. In certain embodiments, the 
nanochannels are fabricated by a sacrificial layer technique 
that provides smooth surfaces and precisely controlled 
15 dimensions. The nanochannels can be formed in between the 
two layers and connect the outlet microchannels with the 
array of inlet microchannels formed in the bottom wafer, 
additionally allowing thin surface layers to be applied to both 
the top and the bottom surfaces independently, in order to 
20 optimize channel properties such as surface charge, hydro-
phobicity, wetting and conductivity. Each inlet and outlet 
microchannel can be connected to one, two, or more 
nanochannels. The height, width, and length of the nanochan-
nel can be used to maintain a constant (zero-order) delivery. 
25 By the help of nanofabrication, a nanochannel length of 10 
mu or less is feasible. 
In certain embodiments, the nanochannel delivery device 
is designed to yield high strength. This can be achieved by a 
supporting structure obtained in the bottom side of the thick 
30 wafer. The structure can be composed by a regular mesh of 
micrometric walls which create the side surfaces of larger 
inlet macrochannels. Moreover, the top portion of the bottom 
wafer (in or on which nanochannels may be fabricated) can be 
35 engineered to provide good mechanical stability. 
The thickness of the supporting layer underneath the 
nanochannels can be optimized, and can be realized by con-
trolling the depth of the inlet microchannels and outlet mac-
rochannels or by selecting an SOI wafer with appropriate 
40 depth of buried oxide layer. The materials and thickness of top 
layers is also optimized for the attributes noted above. 
Certain embodiments include a nanochannel delivery 
device comprising: an inlet microchannel; a nanochannel; 
and an outlet microchannel, wherein the inlet microchannel 
45 and the outlet microchannel are in direct fluid communication 
with the nanochannel. In specific embodiments, the 
nanochannel is oriented parallel to the primary plane of the 
nanochannel delivery device. In particular embodiments, a 
flow path from the inlet microchannel to the nanochannel to 
50 the outlet microchannel requires a maximum of two changes 
in direction. 
In specific embodiments, the inlet microchannel has a 
length, a width, and a depth; the outlet microchannel has a 
length, a width, and a depth; and the nanochannel has a 
55 length, a width, and a depth. In certain embodiments, the ratio 
of the nanochannel length to the inlet microchannel length is 
between 0.01 and 10.0, and the ratio of the nanochannel 
length to the outlet microchannel length is between 0.01 and 
10.0. In particular embodiments, the nanochannel length is 
60 greater than the inlet microchannel length and the nanochan- 
nel length is greater than the outlet microchannel length. In 
specific embodiments, the ratio of the nanochannel length to 
either the inlet microchannel length or the outlet microchan- 
nel length is between 0.2 and 5.0, between 0.3 and 3.0, 
65 between 0.4 and 2.0, or between 0.5 and 1.0. In certain 
embodiments, the nanochannel length is greater than the 
length, width, and depth of the outlet microchannel. In par- 
US 8,480,637 B2 
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tcular embodiments, the inlet microchannel is in direct fluid 
communication with the outlet microchannel via a single 
nanochannel. 
Certain embodiments include a nanochannel delivery 
device comprising: an inlet microchannel; a nanochannel; an 5 
outlet microchannel; and a fluid flow path from the inlet 
microchannel to the outlet microchannel, where the fluid flow 
path requires a maximum of two changes in direction. In 
specific embodiments, the nanochannel is oriented parallel to 
the primary plane of the nanochannel delivery device. In io 
particular embodiments, the inlet microchannel and the outlet 
microchannel are in direct fluid communication with the 
nanochannel. 
Certain embodiments include a nanochannel delivery com-
prising: a substantially planar body comprising a first surface 15 
and a second surface opposing the first surface; a nanochannel 
disposed within the substantially planar body; an inlet micro-
channel in fluid communication with the nanochannel; and an 
outlet microchannel in fluid communication with the 
nanochannel. In particular embodiments, the inlet micro- 20 
channel extends from the nanochannel to the first surface and 
wherein the outlet microchannel extends from the nanochan-
nel to second surface. 
Certain embodiments include a nanochannel delivery 
device comprising: a plurality of inlet microchannels; a plu- 25 
rality of nanochannels; and a plurality of outlet microchan-
nels, where each inlet microchannel is in direct fluid commu-
nication with an outlet microchannel via a single 
nanochannel. In particular embodiments, the nanochannel is 
oriented parallel to the primary plane of the nanochannel 30 
delivery device, and/or an inlet microchannel and an outlet 
microchannel are in direct fluid communication with a com-
mon nanochannel. In particular embodiments, individual 
inlet and outlet microchannels are arranged perpendicular to 
a primary plane of the nanochannel delivery device; the plu- 35 
rality of inlet microchannels form a first array; the plurality of 
outlet microchannels form a second array; and the first array 
and the second array are overlapping so that individual inlet 
microchannels are distributed between individual outlet 
microchannels when viewed along a section taken perpen- 40 
dicular to the primary plane. 
Certain embodiments include a nanochannel delivery 
device comprising: a substantially planar body including: a 
length, a width, and a thickness, wherein the length and the 
width are each greater than the thickness; an inlet surface on 45 
a first side of the substantially planar body, wherein the inlet 
surface is bounded by the length and the width of the substan-
tially planar body; and an outlet surface on a second side of 
the substantially planar body. In particular embodiments, the 
outlet surface is bounded by the length and the width of the 50 
substantially planarbody, andthe inlet surface is substantially 
parallel with the outlet surface. Specific embodiments com-
prise a nanochannel disposed within the substantially planar 
body, where the nanochannel comprises an inlet end and an 
outlet end; an inlet microchannel in fluid communication with 55 
the nanochannel; and an outlet microchannel in fluid commu-
nication with the nanochannel, where the inlet microchannel 
and nanochannel are configured such that a first linear axis 
can extend between the inlet surface and the inlet end of the 
nanochannel. In particular embodiments, the outlet micro- 60 
channel and nanochannel are configured such that a second 
linear axis can extend between the outlet surface and the 
outlet end of the nanochannel. In certain embodiments, a 
primary axis of the inlet microchannel is perpendicular to a 
plane that is parallel to the substantially planar body. Particu- 65 
lar embodiments comprise an inlet macrochannel between 
the inlet surface and the inlet microchannel, where the inlet 
macro channel comprises boundary walls that are generally 
perpendicular to the inlet surface. In specific embodiments, 
the inlet macrochannel is formed by deep reactive-ion etch-
ing. In particular embodiments, a primary axis of the outlet 
microchannel is perpendicular to a plane that is parallel to the 
substantially planar body. 
Certain embodiments comprise an apparatus comprising a 
first nanochannel delivery device inserted into a capsule. In 
particular embodiments, the first nanochannel delivery 
device is installed perpendicular to the primary axis of the 
capsule. In particular embodiments, the capsule comprises a 
septum. In certain embodiments, the septum comprises a 
self-sealing material. In specific embodiments, the septum 
comprises silicone rubber. In certain embodiments, the sep-
tum is configured to receive an injection of a therapeutic 
agent. 
Particular embodiments comprise a cap covering the sep-
tum. In certain embodiments, the cap comprises an orifice 
configured to guide a needle towards the septum. In specific 
embodiments, the capsule comprises a cover extending over 
the first nanochannel delivery device. In particular embodi-
ments, the cover comprises one or more orifices. In certain 
embodiments, the one or more orifices are sized so that they 
do not limit diffusion of a therapeutic agent from the capsule 
during use. In certain embodiments, the cover is configured to 
protect the first nanochannel delivery device from mechanical 
damage. In particular embodiments, the cover is configured to 
protect the first nanochannel delivery device from incursion 
by biological tissue structures after the capsule has been 
implanted in a living body. In certain embodiments, the cap-
sule comprises a first inner reservoir. In specific embodi-
ments, the first nanochannel delivery device is in fluid com-
munication with the first inner reservoir. 
In specific embodiments, the capsule comprises a second 
inner reservoir in fluid communication with a second 
nanochannel delivery device. In certain embodiments, the 
first and second inner reservoir are not in fluid communica-
tion with each other. In particular embodiments, the first and 
second inner reservoir are separated by a wall. In specific 
embodiments, the first inner reservoir contains a first thera-
peutic agent and the second inner reservoir comprises a sec-
ond therapeutic agent. In particular embodiments, the first 
nanochannel delivery is configured to diffuse a first therapeu-
tic agent at a first diffusion rate and the second nanochannel 
delivery device is configured to diffuse the second therapeutic 
agent a second diffusion rate. 
In certain embodiments the volume of the first inner reser-
voir can be modified by replacing a first removable compo-
nent of the capsule with a larger removable component. In 
particular embodiments, the first inner reservoir comprises a 
coating compatible with a therapeutic substance. In specific 
embodiments, the capsule comprises an outer coating config-
ured to prevent deleterious tissue encapsulation. In particular 
embodiments, the capsule comprises a cylindrical shape. In 
certain embodiments, the capsule comprises a disc shape. In 
certain embodiments, the capsule comprises a rectangular 
surface and an arched surface. In specific embodiments, the 
capsule comprises a uniform cross-section. 
In certain embodiments, the capsule comprises one or more 
of the following materials: stainless steel, titanium, poly-
etheretherkeytone, polysulfone, epoxy, silicone rubber, poly-
etherketoneketone, and thermoplastic polyurethane. In par-
ticular embodiments, the capsule comprises an anchor 
member. In certain embodiments, the anchor member is con-
figured to receive a suture. In specific embodiments, the cap-
sule comprises a color coding to indicate a characteristic of 
the capsule or the nanochannel delivery device. In particular 
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embodiments, the color coding indicates a characteristic of a 	 microchannels and inlet macrochannels. In particular 
therapeutic agent contained within the capsule. In specific 	 embodiments of the method, each nanochannel is between 
embodiments the capsule comprises a translucent ortranspar- 	 approximately one and ten nanometers deep, between 
ent cover extending over the first nanochannel delivery 	 approximately ten and twenty nanometers deep, between 
device. 	 5 approximately twenty and thirty nanometers deep, between 
Certain embodiments include a method of fabricating a 	 approximately thirty and forty nanometers deep, or between 
nanochannel delivery device. In particular embodiments, the 	 approximately forty and two hundred nanometers deep. 
method comprises: providing a first substrate; forming a plu- 	 In certain embodiments of the method, the first sacrificial 
rality of nanochannels in the first substrate; forming a plural- 	 material can be subsequently removed by selective etching. In 
ity of inlet microchannels in the nanochannels of the first io particular embodiments, the first sacrificial material is tung- 
substrate; providing a second substrate; forming a plurality of 	 sten. In specific embodiments, the second sacrificial material 
outlet microchannels in the second substrate; and coupling 	 can be subsequently removed by selective etching. In certain 
the second substrate to the first substrate, wherein each inlet 	 embodiments of the method, the second sacrificial material is 
microchannel is in direct fluid communication with a 	 selected from the group consisting of: tungsten, copper, 
nanochannel. 	 15 doped glass, and undoped glass. In particular embodiments, 
In particular embodiments of the method, the first substrate 	 the second sacrificial material is filled into the plurality of 
comprises a silicon-on-insulator wafer. In certain embodi- 	 inlet microchannels so that the second sacrificial material 
ments, the height of each nanochannel is between approxi- 	 extends above the top of the inlet microchannels and is pla- 
mately one and ten nanometers. In specific embodiments, the 	 narized by chemical-mechanical planarization (CMP). 
height of each nanochannel is between approximately ten and 20 In particular embodiments of the method, the capping layer 
twenty nanometers, between approximately twenty and thirty 	 is selected from silicon nitride, silicon oxide, silicon carbo- 
nanometers, between approximately thirty and fifty nanom- 	 nitride, silicon carbide, and silicon. In certain embodiments, 
eters, between approximately fifty and one hundred nanom- 	 the capping layer comprises multiple depositions of materials 
eters, or between approximately one hundred and two hun- 	 comprising tensile and compressive stresses such that the net 
dred nanometers. In certain embodiments the second 25 capping layer stress is tensile. In certain embodiments of the 
substrate comprises a sacrificial release layer of indium tin 	 method, the capping layer is between approximately 0.5 and 
oxide film on silicon. Particular embodiments further com- 	 1.0 microns thick, between approximately 1.0 and 2.0 
prise depositing a glass film on the second substrate prior to 	 microns thick, between approximately 2.0 and 4.0 microns 
forming the plurality of inlet microchannels in the second 	 thick, or between approximately 4.0 and 10.0 microns thick. 
substrate. In specific embodiments, the second substrate com-  30 In specific embodiments, the capping layer is greater than 
prises a glass wafer and the glass wafer is bonded to the first 	 10.0 microns thick. 
substrate and the glass wafer is ground to reduce the thickness 	 Particular embodiments comprise a method of fabricating 
prior to forming the plurality of outlet microchannels. 	 a nanochannel delivery device, where the method comprises: 
Certain embodiments include a method of fabricating a 	 providing a first substrate; forming a plurality of nanochan- 
nanochannel delivery device where the method comprises: 35 nels on a first side of the first substrate; filling in the plurality 
providing first substrate; forming a plurality of nanochannels 	 of nanochannels with  sacrificial material; coupling an initial 
on the first substrate; filling in the plurality of nanochannels 	 capping layer to the first side of the first substrate; forming a 
with a first sacrificial material; forming a plurality of inlet 	 plurality of inlet microchannels in the capping layer; prepar- 
microchannels in the first substrate; filling in the plurality of 
	
ing a second substrate with a bonding layer; coupling the 
inlet microchannels with a second sacrificial material; form-  40 second substrate to a second side of the first substrate; remov- 
ing a capping layer that covers the plurality of nanochannels; 	 ing a first portion of the second substrate; providing an addi- 
forming a plurality of outlet microchannels in the capping 	 tional capping layer to the second substrate; forming a plu- 
layer; removing the first sacrificial material from the plurality 	 rality of outlet microchannels in the second substrate; and 
of nanochannels; and removing the second sacrificial mate- 	 removing the sacrificial material to open the plurality of 
rial from the plurality of inlet microchannels. 	 45 nanochannels. 
In particular embodiments of the method, an inlet micro- 	 In certain embodiments of the method, the second substrate 
channel is arranged perpendicular to a primary plane of the 	 comprises a release layer, and the release layer can be selec- 
first substrate. In specific embodiments, an outlet microchan- 	 tively removed to cause separation of the second substrate 
nel is arranged perpendicular to a primary plane of the first 	 from the first substrate. In particular embodiments of the 
substrate. In certain embodiments of the method, an inlet 50 method, an outlet microchannel is in direct fluid communi- 
microchannel is in direct fluid communication with a 	 cation with the a nanochannel. In certain embodiments, the 
nanochannel. In particular embodiments, an outlet micro- 	 first substrate comprises a silicon-on-insulator wafer com- 
channel is in direct fluid communication with a nanochannel. 	 prising an internal oxide layer. In specific embodiments, 
In certain embodiments of the method, the first substrate 	 forming the plurality of inlet microchannels comprises etch- 
comprises a silicon-on-insulator wafer comprising an internal 55 ing material from the capping layer, and the etching is tenni-
oxide layer. In particular embodiments, the inlet and outlet 	 nated at the internal oxide layer. 
microchannels are patterned using a photolithography pro- 	 In certain embodiments, forming a plurality of inlet mac- 
cess. In certain embodiments, forming the plurality of inlet 	 rochannels comprises etching material from aback side of the 
microchannels comprises etching material from the first sub- 	 first substrate, and the etching is terminated at the internal 
strate, and the etching is terminated at the internal oxide layer. 60 oxide layer. In particular embodiments, the removal of the 
In particular embodiments of the method, forming a plurality 	 internal oxide layer after etching material to form the inlet 
of inlet macrochannels comprises etching material from a 	 microchannel and inlet macrochannels opens a pathway 
back side of the first substrate, and the etching is terminated at 	 between the inlet microchannels and inlet macrochannels. 
the internal oxide layer. 	 In certain embodiments, each nanochannel is formed 
In certain embodiments the removal of the internal oxide 65 between approximately one and ten nanometers deep, 
layer after etching material to form the inlet microchannel 
	
between approximately ten and twenty nanometers deep, 
and inlet macrochannels opens a pathway between the inlet 	 between approximately twenty and thirty nanometers deep, 
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between approximately thirty and forty nanometers deep, or 
between approximately forty and two hundred nanometers 
deep. 
In particular embodiments, the sacrificial material can be 
subsequently removed by selective etching. In specific 
embodiments, the sacrificial material is tungsten. In certain 
embodiments, the initial capping layer is silicon nitride 
deposited by plasma enhanced chemical vapor deposition. In 
certain embodiments of the method, the initial capping layer 
is between approximately 0.01 and 0.5 microns thick, 
between approximately 0.5 and 1.0 microns thick, between 
approximately 1.0 and 2.0 microns thick, between approxi-
mately 2.0 and 4.0 microns thick, or between approximately 
4.0 and 10.0 microns thick. In specific embodiments of the 
method, the initial capping layer is greater than 10.0 microns 
thick. In certain embodiments of the method, the initial cap-
ping layer is selected from silicon nitride, silicon oxide, sili-
con carbonitride, silicon carbide, and silicon. In particular 
embodiments, the initial capping layer comprises multiple 
depositions of materials comprising tensile and compressive 
stresses such that the net capping layer stress is tensile. In 
certain embodiments of the method, the bonding layer is 
selected from the group consisting of benzocyclobutene, sili-
con oxide, copper, doped glass, gold and gold alloys. 
In certain embodiments, the method of coupling the second 
substrate to the first substrate is selected from the group 
consisting of anodic bonding, fusion bonding, and thenno-
compression bonding. 
Particular embodiments include a nanochannel delivery 
device comprising: a plurality of inlet microchannels, where 
each of the inlet microchannels has a length, a width, and a 
depth, and where the inlet microchannel length is greater than 
the inlet microchannel width and depth; a plurality of outlet 
microchannels, where each of the outlet microchannels has a 
length, a width, and a depth; and a plurality of nanochannels 
in fluid communication with the plurality of inlet microchan-
nels and outlet microchannels. In certain embodiments, the 
plurality of inlet microchannels are arranged so that the inlet 
microchannel width and depth define a first plane that is 
parallel to the primary plane of the nanochannel delivery 
device; and the plurality of outlet microchannels are arranged 
so that the outlet microchannel width and depth define a 
second plane that is parallel to the primary plane of the 
nanochannel delivery device. 
Particular embodiments include a method of treating a 
condition of a person, the method comprising: providing a 
nanochannel delivery device as described herein; providing a 
reservoir in fluid communication with the nanochannel deliv-
ery device; providing a substance in the reservoir, where the 
substance is configured to treat the condition; and adminis-
tering the substance to the person via the nanochannel deliv-
ery device. In particular embodiments of the method, the 
substance is selected from the group consisting of: leuprolide, 
letrozole, laptinib, buprenorphine, interferon, and zidovu-
dine. In certain embodiments, the condition is selected from 
the group consisting of: prostate cancer, breast cancer, opiate 
dependency, giant cell angioblastoma and HIV. In particular 
embodiments of the method, administering the substance to 
the person via the nanochannel delivery device comprises 
subcutaneously inserting the nanochannel delivery device 
into the person. 
In the following, the term "coupled" is defined as con-
nected, although not necessarily directly, and not necessarily 
mechanically. 
The use of the word "a" or "an" when used in conjunction 
with the term "comprising" in the claims and/or the specifi-
cation may mean "one," but it is also consistent with the 
8 
meaning of "one or more" or "at least one." The term "about' 
means, in general, the stated value plus or minus 5%. The use 
of the term "or" in the claims is used to mean "and/or" unless 
explicitly indicated to refer to alternatives only or the alter- 
s native are mutually exclusive, although the disclosure sup-
ports a definition that refers to only alternatives and "and/or." 
The terms "comprise" (and any form of comprise, such as 
"comprises" and "comprising"), "have" (and any form of 
have, such as "has" and "having"), "include" (and any form of 
to include, such as "includes" and "including") and "contain" 
(and any form of contain, such as "contains" and "contain-
ing") are open-ended linking verbs. As a result, a method or 
device that "comprises," "has," "includes" or "contains" one 
15 or more steps or elements, possesses those one or more steps 
or elements, but is not limited to possessing only those one or 
more elements. Likewise, a step of a method or an element of 
a device that "comprises," "has," "includes" or "contains" one 
or more features, possesses those one or more features, but is 
20 not limited to possessing only those one or more features. 
Furthermore, a device or structure that is configured in a 
certain way is configured in at least that way, but may also be 
configured in ways that are not listed. 
The term "inlet microchannel" is defined as a microchan-
25 nel through which a molecule travels prior to entering a 
nanochannel in a nanochanneled delivery device. 
The term "outlet microchannel" is defined as a microchan-
nel through which a molecule travels immediately prior to 
exiting a nanochanneled delivery device. 
30 	 The term "nanochannel" is defined as a channel with a 
cross-section having at least one dimension (e.g. height, 
width, diameter, etc.) that is less than 200 mu. 
The term "macrochannel" is defined as a channel with a 
cross-section having a maximum dimension (e.g. height, 
35 width, diameter, etc.) that is greater than about 10 µm. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indicat- 
40 ing specific embodiments of the invention, are given by way 
of illustration only, since various changes and modifications 
within the spirit and scope of the invention will be apparent to 
those skilled in the art from this detailed description. 
45 	 BRIEF DESCRIPTION OF THE FIGURES 
FIGS. 1A-1J are schematic views of a manufacturing pro-
cess according to an exemplary embodiment. 
FIGS. 2A-2E are perspective views of a first portion of a 
5o nanochannel delivery device during the manufacturing pro-
cess. 
FIGS. 3A-3F are perspective views of a second portion of 
a nanochannel delivery device during the manufacturing pro-
cess. 
55 	 FIG. 3G is a partial perspective view of a nanochannel 
delivery device with representative dimensions labeled. 
FIG. 4A-4L are schematic views of a manufacturing pro-
cess according to an exemplary embodiment. 
FIGS. 5A-5H are schematic cross-section views of a 
6o nanochannel delivery device during the manufacturing pro-
cess according to an exemplary embodiment. 
FIGS. 6A-6J are schematic views of a manufacturing pro-
cess according to an exemplary embodiment. 
FIG. 7 is a cross-sectional side view of a schematic of an 
65 exemplary embodiment of a nanochannel delivery device. 
FIGS. 8A-8I are schematic views of a manufacturing pro- 
cess according to an exemplary embodiment. 
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FIGS. 87-8P are orthogonal and perspective views of 
exemplary embodiments during various stages of the manu-
facturing process. 
FIG. 9 is a perspective view of a nanochannel delivery 
device according to an exemplary embodiment. 
FIG. 10 is a cross-sectional side view of a schematic of an 
exemplary embodiment of a nanochannel delivery device. 
FIG. 11 is a scanning electron microscope image of a 
portion of a nanochannel delivery device according to an 
exemplary embodiment. 
FIG. 12 is an optical image of a bonded wafer of a 
nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 13 is an optical image of a front surface of a nanochan-
nel delivery device according to an exemplary embodiment 
after polishing. 
FIG. 14 is a scanning electron microscope image of a 
portion of a nanochannel delivery device according to an 
exemplary embodiment. 
FIG. 15 is an optical image of a portion of a nanochannel 
delivery device according to an exemplary embodiment after 
polishing. 
FIG. 16 is scanning electron microscope image of a portion 
of a nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 17 is scanning electron microscope image of a portion 
of a nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 18 is a table of materials that may be used in exem-
plary embodiments of manufacturing processes. 
FIG. 19 is an exploded perspective view of a capsule and a 
nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 20 is an assembled perspective view of the embodi-
ment of FIG. 19. 
FIG. 21 is an assembled perspective view of a capsule 
according to an exemplary embodiment. 
FIG. 22 is an exploded perspective view of the embodiment 
of FIG. 21. 
FIG. 23 is an exploded perspective view of a capsule and a 
nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 24 is an exploded perspective view of a capsule and a 
nanochannel delivery device according to an exemplary 
embodiment. 
FIG. 25 is an assembled perspective view of a capsule 
according to an exemplary embodiment. 
FIG. 26 is an exploded perspective view of the embodiment 
of FIG. 25. 
FIG. 27 is an assembled perspective view of a capsule 
according to an exemplary embodiment. 
FIG. 28 is an exploded perspective view of the embodiment 
of FIG. 27. 
FIG. 29 is a perspective view of a capsule according to an 
exemplary embodiment. 
FIG. 30 is a perspective view of a capsule according to an 
exemplary embodiment in an installed location. 
FIG. 31 is a perspective view and a section view of a 
capsule according to an exemplary embodiment. 
DETAILED DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
Protocol I 
Bonded Capping Layer 
FIGS. la-1j, 2A-2E, and 3A-3G provide illustrations of 
steps performed in an exemplary first method of manufactur- 
10 
ing a nanochannel delivery device. Specific dimensions are 
provided for purposes of illustration only, and it is understood 
that other exemplary embodiments may comprise different 
dimensions. 
5 	 In one exemplary embodiment manufactured according to 
this protocol, the top layer is a cover of a 5 µm thick evapo-
rated glass layer and the bottom wafer is a 4 inch SOI wafer 
with a 30 µm device layer, and a 500 µm bulk layer, so that the 
supporting layer under the nanochannels has 30 µm thickness. 
io Inthis exemplary structure, the inlet and outlet microchannels 
are 5 µm by 5 µm, and the in-plane dimension of each 
nanochannel is 5 µm by 5 µm. The space between adjacent 
openings (e.g., the distance between adjacent nanochannels) 
is 2 µm. The inlet macrochannel under the support network is 
15 approximately 200 µm by 200 µm up through the 500 µm 
thick bulk layer. 
A general overview of this method of manufacturing will 
first be presented, followed by a more detailed discussion of 
the features comprised in the nanochannel delivery device. In 
20 this embodiment, fabrication of the nanochannel delivery 
device does not utilize chemical mechanical polishing 
(CMP), and the microfabrication protocol comprises the fol-
lowing steps. Starting with a SOI (silicon on insulator) wafer 
(see FIG. 2A), a hard mask layer such as silicon nitride film or 
25 LTO (low temperature oxidation) film that will protect under-
neath silicon during thermal oxidation process is deposited. If 
silicon nitride is used, a silicon dioxide pad layer may be 
deposited before nitride deposition. As an alternative, the 
bottom substrate can also be a silicon wafer instead of SOI if 
30 the etching process rates are well characterized. In this case, 
the etching depth is controlled by timing. 
The nanochannel areas can then be patterned on the mask 
layer using photolithography process. (see FIGS. 1(a) and 
213), and the mask materials on nanochannel areas are selec- 
35 tively removed but do not affect underneath silicon. A com-
bination of dry etching, and short time wet etching may be 
applied for this purpose. Then a silicon dioxide film (with a 
thickness that is well-controlled) can be deposited on bare 
silicon area by thermal oxidation. In this embodiment, the 
40 thickness of the oxidation layer is used to define the height of 
nanochannels, and the mask layer is stripped. 
A mask layer suitable for deep silicon etching can then be 
deposited. The mask layer should be able to be patterned, and 
have a high selectivity to silicon during deep silicon etching 
45 process. Depending on the technique for deep silicon etching, 
a layer of silicon oxide, photoresist, or metal film may be 
used. 
In this embodiment, the inlet microchannels are patterned 
on the mask layer, and the inlet microchannels are etched 
5o down to the oxide layer of the SOI wafer by deep RIE (Reac-
tive Ion Etch) or ICP (Inductive Coupled Plasma) technique, 
as shown FIGS. 1(b) and 2C. If a silicon wafer is used, the 
etching depth is determined by etching rate and time. 
The inlet macrochannels (the large openings from the 
55 back) are laid out and etched to the oxide layer of SOI wafer, 
as shown in FIGS. 1(c) and 2D, and the exposed oxide areas 
are cleaned by HE solution. (see FIGS. 1(d) and 2E). To 
fabricate the top cover of the nanochannel delivery devices in 
this embodiment, starting with a support wafer (e.g., a silicon 
60 wafer), a sacrificial layer is deposited. (see FIGS. 1(e), 1(f) 
and 3A). This sacrificial layer (e.g., indium tin oxide (ITO)), 
is selected so that it can be removed in a solution that is safe 
for silicon and top cover materials. 
The top cover of the nanochannel delivery devices is 
65 deposited on the sacrificial layer (see FIGS. 1(g) and 313), and 
the outlets are patterned on the structure, as shown in FIGS. 
1(h) and 3C). As an alternative, a lift-off technique may be 
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applied for the cases of sputtered glass or e-beam evaporated 	 understood, the designations "upper" and "lower" are used 
glass. The materials may be any suitable material, e.g. spin- 	 only for purposes of clarification in the description of the 
on-glass, sputtered glass, e-beam evaporated glass, ITO-glass 	 figures, and do not dictate the relationship of components 
sandwich, silicon, polymer, etc. The materials may include 	 during use of the device. As shown in FIGS. 3D and 3E, upper 
glass and glass materials known to those skilled in the art to 5 portion 45 and lowerportion 40 are bonded together (through, 
bond to silicon by specific means, e.g., anodic bonding or 	 e.g., anodic bonding or Si Si direct bonding or intermediate 
fusion bonding. The materials should be able to bond to 	 layer aided bonding). Support substrate 55 is removed from 
silicon by certain means. For instance of glass, anodic bond- 	 upper portion 45, and nanochannel delivery device 100 is 
ing can be applied. A spin-on-glass layer may also applicable. 	 completed, as shown in FIGS. 3F and 3G. The embodiment 
Depending on the surface quality, a planarization process 10 shown in FIG. 3G comprises optional tapered surfaces in the 
may be needed. 	 transitions between outlet microchannels 70 and nanochan- 
The structure wafer and the top cover are bonded together 	 nels 25, as well as between nanochannels 25 and inlet micro- 
by a technique such as anodic bonding or Si Si direct bond- 	 channels 30. 
ing or intermediate layer aided bonding, as shown in FIGS. 	 As shown in FIG. 3G, nanochannels 25 lie in a plane 
1(c), 3D, and 3E, and the support wafer of top cover is 15 parallel to the primary plane of nanochannel delivery device 
removed (as shown in FIGS. 1(j) and 3F). Finally, the indi- 	 100 (e.g., the plane defined by the larger dimensions [in this 
vidual nanochannel delivery devices are obtained by dicing 	 example, L and W] of nanochannel delivery device 100). 
the wafer, and cleaning. 	 Such a configuration allows for the length of nanochannel 25 
In another exemplary embodiment manufactured accord- 	 (e.g., approximately the distance between adjacent outlet 70 
ing to this protocol, while keeping the bottom silicon sub-  20 and inlet 30) and the height and width of the nanochannel to 
strate is the same 4 inch SOI wafer with a 30 µm device layer 	 be varied without varying the length L, width W, and thick- 
and a 500 µm bulk layer as that mentioned in above embodi- 	 ness T of nanochannel delivery device 100. The thickness T of 
ment, the top layer is a 10 M thick glass film. The 10 um thick 	 nanochannel delivery device 100 can therefore be based on 
glass film is manufactured by thinning a thicker glass layer. 	 other criteria (such as mechanical integrity) rather than the 
To make this thin film, a 100 um to 500 um thick glass wafer 25 need to control the flow of a substance being delivered via 
is bonded to the structural silicon substrate. A planarization 	 nanochannel delivery device 100. 
technique such as backgrinding, or lapping, or CMP, or 	 The embodiments shown in FIGS. 3A-3G also provide for 
chemical etching, or dry etching is then applied to thin the 	 each outlet 70 to be in fluid communication with any inlet 30 
glass layer until the designed thickness such 10 um is reached. 	 via a single nanochannel 25. Such a configuration can provide 
The outlets are then patterned on the thinned glass film, and 30 for greater control over the diffusion of a substance being 
etched down to the underneath silicon surface to open the 	 delivered via nanochannel delivery device 100. For example, 
outlets. In this exemplary structure, the inlet and outlet micro- 	 the diffusion rate through nanochannel delivery device 100 is 
channels are 5 µm by 5 µm, and the in-plane dimension of 	 more closely related to the dimensions of nanochannel 25, as 
each nanochannel is 5 µm by 5 µm. The space between adja- 	 compared to configurations that have numerous nanochan- 
cent openings (e.g., the distance between adjacent nanochan-  35 nels in fluid communication with a single extended inlet. In 
nels) is 2 µm. The inlet macrochannel under the support 	 such configurations, the inlet (rather than the nanochannel) 
network is 200 µm by 200 µm up through the 500 µm thick 	 may become a restriction on flow and limit the ability to 
bulk layer. 	 control the flow by varying the dimensions of the nanochan- 
Referring specifically now to FIGS. 2A-2E and 3A-3F, a 	 nel. 
more detailed view of the features of nanochannel delivery 40 	 As shown in the detailed view of FIG. 3G (not to scale), 
device 100 is provided. Referring initially to FIG. 2A, an SOI 	 nanochannel 25 comprises a length nL, a width nW and a 
wafer 10 comprises a top layer 15 over a substrate 20 and 	 height nH. Outlet microchannel 70 comprises a length oL, a 
separated by an oxide layer 35. As shown in FIG. 213, a series 	 width o W, and a height oH. In addition, inlet microchannel 30 
of nanochannels 25 are formed using a pattern mask in top 	 comprises a length iL, a width iW and a height iH. As shown 
layer 15. One or more inlet microchannels 30 is formed using 45 in FIG. 3G, the "length" of each channel is measured along 
a pattern mask in each nanochannel 25, as shown in FIG. 2C, 	 the path that a molecule would travel as it moves from inlet 
exposing an oxide layer 35 between the substrate 20 and the 	 microchannel 30, through nanochannel 25, and out through 
top layer 15. For purposes of clarity not all features, for 	 outlet microchannel 70. In certain embodiments oL=4 um, 
example inlet microchannels 30, are labeled in the figures. 	 oW-5 um, off-5 um while nH=50 mu, nW=4 um, and nL -5 
As shown in FIG. 2D, a portion of substrate 20 is removed 50 um and oL=30 um, oW-5 um, off-5 um. 
using a pattern mask from below the oxide layer 35. Oxide 	 In certain embodiments, the ratio of oL/nL or iL/nL can be 
layer 35 is then removed (as shown in FIG. 2E), and inlet 	 0. 1, 0. 2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.1, 1.2, 1.3, 1.4, 1.5, 
microchannels 30 are formed to allow passage of material 	 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 
through the substrate 20 and top layer 15. At this stage, the 	 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 
lower portion 40 of nanochannel delivery device 100 is com-  55 4.4, 4.5, 4.6, 4.7, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 
plete. 	 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 
Referring now to FIGS. 3A-3F, the fabrication of the upper 	 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 
portion 45 of nanochannel delivery device 100 begins with a 	 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 
sacrificial layer 50 deposited on a support substrate 55. In 	 20, 30, 40 50, 60, 70, 80, 90, or 100. 
addition, an additional layer 60 (e.g., spin-on-glass, sputtered 60 
glass, e-beam evaporated glass, ITO-glass sandwich, silicon, 	 Protocol 2 
polymer, etc.) may be used in processes utilizing a lift-off 
technique, as shown in FIG. 3B. Exit microchannels 70 are 	 Multilayered Structure with Bonded Capping Layer 
formed in sacrificial layer (and additional layer 60, if utilized) 
as shown in FIG. 3C. 	 65 In a second embodiment, a multilayered nanochannel 
At this stage, upper portion 45 is ready to be bonded to 	 structure can be fabricated by modifying the above-described 
lower portion 40 of nanochannel delivery device 100. It is 	 protocol 1. This embodiment comprises the following steps. 
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Starting with a SOI (silicon on insulator) silicon wafer, a 
silicon dioxide layer (witha thickness that is well-controlled) 
is deposited by thermal oxidation. The thickness of the oxi-
dation layer can be used to define the height of nanochannels. 
As an alternative, the bottom substrate can also be silicon 
wafer instead of SOI if the etching process rates are well 
characterized. The nanochannel areas can be patterned on the 
oxide layer using photolithography process. 
The silicon oxide on non-nanochannel areas can be selec-
tively removed but not affect the oxide on nanochannel area. 
(See FIG. 4(a)). A polysilicon structure layer can be depos-
ited on the top of oxide nanochannel spacing layer. (see FIG. 
4(b)). A second defined thickness oxide layer can be depos-
ited again, and the nanochannel areas can be patterned on the 
oxide layer using photolithography process. The silicon oxide 
on non-nanochannel areas can be selectively removed but do 
not affect the oxide on nanochannel area. (See FIG. 4(c)). 
This process finishes the second layer of nanochannels. The 
previous two steps can be repeated to achieve desired number 
of layers. 
As an alternative to the previous steps, the silicon oxide 
nanochannel spacing layer and multilayer structure layer may 
also use other materials. For example, an aluminum film as 
nanochannel spacing layer, and evaporated glass film as mul-
tilayer structure layers. 
A first mask layer suitable for deep silicon etching can be 
deposited. The mask layer should be able to be patterned, and 
have high selectivity to silicon during deep silicon etching 
process. Depending on the technique for deep silicon etching, 
a layer of silicon oxide, photoresist, or metal film may be 
used. 
The inlet microchannels are patterned on the first mask 
layer, and a second mask layer is deposited on the top of first 
mask layer. The inlet microchannels are patterned on the both 
first and second mask layers. The outlet microchannels are 
etched down to a certain depth close to oxide layer of the SOI 
wafer, and the second masklayer is stripped to expose the first 
mask layer. The outlet microchannel is etched through mul-
tiple layers of the nanochannel spacing layer and structure 
layer. A combination of wet etching and DRIE may be 
applied. This will also etch the inlet down to the insulator 
layer of SOI wafer. (See FIG. 4(d)). If a silicon wafer is used, 
the etching depth is determinedby etching rate and time. Then 
the inlet macrochannels on the back are laid out and etched to 
the oxide layer of SOI wafer (see FIG. 4(e)), and the oxide on 
the exposed areas is cleaned. (See FIG. 4(f)). 
To fabricate the top cover of the nanochannel delivery 
devices, starting with a support wafer (e.g., a silicon wafer), a 
sacrificial layer is deposited. (See FIG. 4(h)). This sacrificial 
layer is selected so that it can be removed in a solution that is 
safe for silicon and top cover materials. The top cover of the 
nanochannel delivery device is deposited on the supporting 
wafer and the inlet microchannels are etched. A lift off tech-
nique may be applied for certain cases. (See FIG. 4(i j)). The 
materials may include, for example, spin-on-glass, sputtered 
glass, e-beam evaporated glass, ITO-glass sandwich, silicon, 
etc. The materials should be able to bond to silicon by some 
means. For instance, a transparent glass layer can be depos-
ited by e-beam evaporation. A spin-on-glass layer may also 
usable. Depending on the surface quality, a planarization may 
be needed. The structure wafer from the previous step and the 
top cover can be bonded together by a technique such as 
anodic bonding or Si Si direct bonding or intermediate 
layer aid bonding. (See FIG. 4(k)). The support wafer of top 
14 
cover can be removed (See FIG. 4(Z)), and the devices 
obtained by dicing the wafer and cleaning. 
Protocol 3 
Monolithically Fabricated Capping Layer 
As a third embodiment, a nanochannel structure can be 
fabricated monolithically (e.g., without bonding) and option- 
io ally utilizing CMP in the process. This exemplary microfab-
rication protocol comprises the following steps as shown in 
FIGS. 5A-5H. 
Specific dimensions are provided for purposes of illustra-
tion only, and it is understood that other exemplary embodi- 
15 ments may comprise different dimensions. In this embodi-
ment, the top layer is approximately 2 µm of deposited silicon 
nitride. This embodiment also comprises a bottom wafer that 
is a 8 inch SOI wafer with a 30 µm device layer, and a 725 µm 
bulk layer, so that the supporting layer under the nanochan- 
2o nels has 30 µm thickness. In this exemplary structure, the 
openings for the inlet and outlet microchannels are 3 µm by 5 
µm, and the in-plane dimension of each nanochannel is 3 µm 
by 5 µm. The space between adjacent microchannel openings 
is 2 µm. As in previously-described embodiments, the inlet 
25 macrochannel under the support network is approximately 
200 µm by 200 µm up through the 725 µm thick bulk layer. 
Starting with an SOI (silicon on insulator) wafer 210, a 
nanochannel spacing layer 220 (with a thickness that is well 
controlled, for example, ±5% over the relevant portion of SOI 
30 wafer 210) is deposited. The thickness of spacing layer 220 
can be used to define the height of the nanochannels. This 
spacinglayer220 is a sacrificial layer, and the material will be 
removed in a subsequent step, so the silicon surface immedi-
ately under it is the "floor" of the eventually formed 
35 nanochannels. The spacing material should have a high wet 
etch selectivity to other materials in the nanochannel delivery 
device (nDD). As an example, a thin film of tungsten, germa-
nium, or silicon oxide can be used for the nanochannel spac-
ing layer 220. 
40 	 As shown in FIG. SA,a capping layer230is deposited over 
the nanochannel spacing layer 220. Capping layer 230 will 
ultimately be the "ceiling" of the nanochannels. Silicon 
nitride, silicon oxide, silicon carbide, or other material which 
has a high etch selectivity to the material for spacing layer 220 
45 may be used for capping layer 230. 
A mask layer (not shown) suitable for deep reactive-ion 
etching (DRIE) is deposited, and the inlet microchannels 240 
are patterned on the mask layer using photolithography. As 
shown in FIG. 513, the DRIE process(es) etch microchannels 
5o 240 through the capping layer 230 and spacing layer 220 and 
silicon down to the buried oxide layer 250 of SOI wafer 210. 
The mask layer can then be removed. 
As shown in FIG. 5C, inlet microchannels 240 are filled 
with a fill material 260 that canbepolishedby CMP or etched. 
55 Non-limiting examples of fill material 260 include copper, 
tungsten, polysilicon, or phosphosilicate glass, each depos-
ited by techniques known in the art. Fill material 260 should 
have a wet etch with high selectivity to silicon and the mate-
rial of capping layer 230. In this exemplary embodiment, fill 
60 material 260 only needs to fill in the top of inlet microchan-
nels 240. A CMP or etch back process can be used to remove 
the excess fill material 260 that extends above or outside of 
inlet microchannels 240. The surface of the remaining fill 
material 260 should be above the level of spacing layer 220. 
65 Referring now to FIG. 5D, additional material may be 
deposited onto capping layer 230. The areas of capping layer 
230 and spacing layer 220 above and between the inlet micro- 
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channels 240 can be patterned using a photolithography pro-
cess. The spacing layer 220 and capping layer 230 outside of 
the inlet nanochannels 240 (e.g., regions 221 and 231) can be 
etched to or slightly below the silicon surface. 
Referring now to FIG. 5E, a final capping layer 270 is 
deposited over the entire surface of wafer 210 to provide 
structural rigidity and seal the sidewalls of the nanochannel 
areas. Using a photolithography process, outlet microchan-
nels 280 can be patterned and etched through capping layers 
23 0, 270 and optionally through spacing layer 220 into silicon 
210 for additional process latitude. As shown in FIG. 5F, a 
protective layer 275 is deposited over capping layer 270 and 
outlet microchannels 280. 
Referring now to FIG. 5G, wafer 210 can then be inverted 
and large openings for inlet macrochannels 245 on the back of 
wafer 210 can be formed by DRIE down to the buried oxide 
layer 250 of wafer 210. As shown in FIG. 5H, sacrificial and 
protective layers used during processing (e.g. spacing layer 
220, fill material 260, capping layer 270, and portions of 
oxide layer 250) are removed by appropriate processes 
known in the art. As shown in FIG. 5H, when spacing layer 
220 is removed, nanochannels 205 are formed. The wafers 
can then be diced to get individual nanochannel delivery 
devices. 
As illustrated in this embodiment, nanochannels 205 are in 
direct fluid communication with inlet microchannels 240 and 
outlet microchannels 280. Specifically, inlet microchannels 
240 and nanochannels 205 are directly connected so that a 
fluid exiting an inlet microchannel will immediately enter the 
nanochannel without flowing through an intermediate body. 
As a variant of this protocol, and in analogy to protocol 2 
above, a multilayered structure can be built by repeated appli-
cation of the monolithic top layer process. A plurality of 
capping layer 230 and spacing layer 220 pairs can be depos-
ited. The inlet microchannels can be etched through all layers 
down to the buried oxide and filled with fill material 260 and 
polished as above. The final capping layer 270 can be applied 
and outlet microchannels 280 etched as above. 
Protocol 4 
Varying the Length of Nanochannels 
In certain embodiments, Protocol 1 can be modified to 
make a nanochannel delivery device with different a 
nanochannel length while keep other features unchanged. An 
exemplary microfabrication protocol comprises the follow-
ing steps. 
Starting with a SOI (silicon on insulator) wafer, a hard 
mask layer such as silicon nitride film or LTO (low tempera-
ture oxidation) film that will protect the underneath silicon 
during thermal oxidation process is deposited. If silicon 
nitride is used, a silicon dioxide pad layer may be deposited 
before nitride deposition. As an alternative, the bottom sub-
strate can also be silicon wafer instead of SOI if the etching 
process rates are well characterized. 
The nanochannel areas can be patterned on the mask layer 
using photolithography process. (See FIG. 6(a)), and the 
mask materials on nanochannel areas are selectively removed 
but do not affect underneath silicon. A combination of dry 
etching, and short time wet etching may be applied for this 
purpose. A silicon dioxide film (with a well-controlled thick-
ness) is deposited on the bare silicon area by thermal oxida-
tion. The thickness of the oxidation layer defines the height of 
nanochannels, and the mask layer and oxide is stripped. 
A mask layer suitable for potassium hydroxide (KOH) wet 
etching is deposited, such as silicon nitride. A new mask is 
designed to lay-out both inlet microchannels and outlet 
microchannels on the same layer, and the nanochannel length 
is defined by the spacing between adjacent inlet and outlet 
microchannels. The mask layer is patterned using the new 
5 mask by standard photolithography process. The mask mate-
rials on open areas are selectively removed. Then a KOH wet 
etching is applied to form openings with the slope wall, and 
the mask layer is stripped. (See FIG. 6(b)). 
A mask layer suitable for deep silicon etching can be 
l0 deposited. The mask layer should be able to be patterned, and 
have a high selectivity to silicon during deep silicon etching 
process. Depending on the technique for deep silicon etching, 
a layer of silicon oxide, photoresist, metal film, or other 
15 suitable material may be used. 
The outlet microchannels are patterned on the mask layer 
and the outlet micro channels are etched down to the oxide 
layer of the SOI wafer by a suitable technique, for example a 
deep RIE or ICP technique. (See FIG. 6(c)). If a silicon wafer 
20 is used, the etching depth can be determined by etching rate 
and time. 
The inlet macrochannels from the back are laid out and 
etched to the oxide layer of the SOI wafer, and the exposed 
oxide areas are cleaned by HF solution. (See FIG. 6(d)). To 
25 fabricate the top cover of the nanochannel delivery devices, 
starting with a support wafer (e.g., silicon wafer), a sacrificial 
layer is deposited. (See FIG. 6(e, fi). This sacrificial layer 
(e.g. ITO), is selected so that it can be removed in a solution 
that is safe for silicon and top cover materials. 
30 	 The top cover of the nanochannel delivery devices is 
deposited on the sacrificial layer. (See FIG. 6(g)), and the 
outlets are patterned on the structure. (See FIG. 6(h)). As an 
alternative, a lift-off technique may be applied for the cases of 
sputtered glass or e-beam evaporated glass. In certain 
35 embodiments, the materials may be spin-on-glass, sputtered 
glass, e-beam evaporated glass, ITO-glass sandwich, silicon, 
polymer, etc. The materials should be able to bond to silicon 
by certain means. For instance of glass, anodic bonding can 
be applied. A spin-on-glass layer may also applicable. 
40 Depending on the surface quality, a planarization process 
may be needed. 
The structure wafer from step (6) and the top cover can be 
bonded together by a technique such as anodic bonding or 
Si Si direct bonding or intermediate layer aided bonding. 
45 (See FIG. 6(i)). The support wafer of top cover is removed 
(See FIG. 6(j)), and the devices are obtained by dicing the 
wafer, and cleaning. 
If the preferred length of nanochannel is less than 500 mu, 
a nanofabrication technique such as e-beam or nanoimprint 
50 may be applied. Isotropic silicon etching technique may also 
be applied. A schematic structure view of a short nanochannel 
delivery device is shown in FIG. 7. As shown in FIG. 7, inlet 
microchannel 340 has a portion 341 that is flared or tapered 
proximal to nanochannel 305. Similarly, outlet microchannel 
55 380 has a portion 381 that is flared or tapered proximal to 
nanochannel 305. Nanochannel 305 is therefore shortened as 
a result of portions 341 and 381. 
Protocol 5 
60 
Hybrid Monolithic-Bonded Capping Layer 
As a fifth embodiment, a nanochannel structure can be 
fabricated without the use of a CMP process, while utilizing 
65 bonding as a non-critical step in the capping layer fabrication. 
This exemplary microfabrication protocol comprises the fol-
lowing steps as seen in FIGS. 8A-8P. 
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Referring initially to FIG. 8A, starting with an SOI (silicon 
on insulator) substrate wafer 410, a nanochannel spacing 
layer 420 (with a thickness that is well-controlled, for 
example, ±5% over the relevant portion of SOI substrate 
wafer 410) is deposited. The thickness of spacing layer 420 5 
can be used to define the height of the nanochannels. This 
spacing layer 420 is a sacrificial layer, and the material will be 
removed in a subsequent step, so the silicon surface immedi-
ately under it is the "floor" of the eventually formed 
nanochannels. The spacing material should have a high wet io 
etch selectivity to all other materials in the nanochannel deliv-
ery device. As an example, a thin film of tungsten, germa-
nium, or silicon oxide can be used for nanochannel spacing 
layer 420. 
Acapping layer430 is deposited overnanochannel spacing 15 
layer 420. Capping layer 430 will ultimately be the "ceiling" 
of the nanochannels. Silicon nitride, silicon oxide, silicon 
carbide, or other material which has a high wet etch selectiv-
ity to the material for spacing layer 420 may be used for 
capping layer 430. The nanochannel areas can be patterned on 20 
spacing layer 420 and capping layer 430 using a photolithog-
raphy process. As shown in FIG. 813, spacing layer 420 and 
capping layer 430 on non-nanochannel areas 432 and 433 are 
etched to or slightly below the silicon surface of silicon wafer 
410. 25 
Referring now to FIG. 8C, additional capping material 431 
is deposited, and optionally planarized by CMP to provide a 
flat surface. Inlet microchannels 440 are patterned on the 
mask layer (not shown) using photolithography. The DRIE 
process(es) etch inlet microchannels 440 through the capping 30 
layer 430 and spacing layer 420 and silicon down to a buried 
oxide layer 450 of SOI substrate wafer 410. The mask layer is 
removed and additional appropriate surface layers useful for 
bonding can be deposited on this surface, as needed. 
Referring now to FIG. 8D, on another silicon substrate (e.g. 35 
a capping wafer 411), a layer 421 (comprising, for example, 
silicon nitride or silicon oxide) can be deposited. On top of 
layer 421, a bonding layer 441 is deposited. The material for 
bonding layer 441 can be chosen so as to adhere well to the 
material on the surface of wafer 410 (e.g. capping material 40 
431). The material for bonding layer 441 can also be designed 
so that any surface particles can be absorbed into bonding 
layer 441 to prevent any delamination between capping wafer 
410 and substrate wafer 411 after bonding. Alternatively, a 
highly clean process before and during bonding can be used 45 
without this requirement. Exemplary materials for bonding 
layer 441 include polymeric materials, silicon oxide, and 
copper. Before the application of bonding layer 441, option-
ally, a material with a very high etch rate, "the release layer" 
421, can also be applied with an additional silicon nitride or 50 
silicon oxide layer (not shown) on top of this release layer. 
Layer 421 can comprise a material with a high selectivity to 
other materials in the nanochannel delivery device. 
Referring now to FIG. 8E, capping wafer 411 and substrate 
wafer 410 are then bonded onto each other. In certain embodi- 55 
ments, the bonding can be polymer-silicon nitride bond, such 
as Benzocyclobutene (BCB)-silicon nitride, copper-copper 
then nocompression bond or oxide-to-oxide fusion bond, 
each with appropriate pre- and post-bond treatments known 
to those skilled in the art. 60 
Referring now to FIG. 8F, the silicon portion of capping 
wafer 411 is then removed through a suitable process, e.g. 
mechanical thinning, a chemical etch, or a combination of 
both. In the case of the optionally added "release layer" 421, 
the release layer can be selectively removed to cause separa- 65 
tion of the silicon capping wafer 411 from substrate wafer 
410. 
Referring now to FIG. 8G, using a photolithography pro-
cess, outlet microchannels 480 can be patterned and etched 
through optional release layer 421, bonding layer 441, cap-
ping material 431, capping layer 430, and optionally through 
spacing layer 420 into the silicon for additional process lati-
tude. 
Referring now to FIG. 8H, a protective capping layer 470 is 
deposited over the surface of substrate wafer 410. Wafer 410 
(with layer 421 and bonding layer 441 from wafer 411) is then 
inverted and inlet macrochannels 445 on the back of wafer 
410 can be formed by DRIE down to the buried oxide layer 
450 of wafer 410. 
Referring now to FIG. 8I, sacrificial layers (e.g. spacing 
layer 420, capping layer 470, and portions of oxide layer 450) 
are removed by appropriate processes known in the art. As 
shown in FIG. 8I, when spacing layer 420 is removed, 
nanochannels 405 are formed. As illustrated in this embodi-
ment, nanochannels 405 are in direct fluid communication 
with inlet microchannels 440 and outlet microchannels 480. 
Referring now to FIG. 87, a top view of the entire wafer 410 
is illustrated. As shown in this view, wafer 410 (prior to 
dicing) comprises several nanochannel delivery devices 400 
(only one of which is identified in the figure). Wafer 410 can 
be diced to separate the individual nanochannel delivery 
devices 400 from each other. A detailed view of an individual 
nanochannel delivery device 400 with exemplary dimensions 
is illustrated in FIG. 8K. In this view, a plurality of inlet 
macrochannels 445 are visible on one side of nanochannel 
delivery device 400. This exemplary embodiment of 
nanochannel delivery device 400 is approximately 6.0 mm 
square, and the inlet macrochannels form a generally circular 
shape approximately 3.6 mm in diameter. It is understood that 
while wafer 410 of Protocol 5 is illustrated in FIG. 87, other 
protocols will also yield wafers that comprise multiple 
nanochannel delivery devices, and can be diced or separated 
into the individual devices. It is also understood that other 
exemplary embodiments may comprise different dimensions 
than those shown in FIG. 8K. In some embodiments, the 
wafer 410 may remain whole, effectively forming a 
nanochannel delivery device with dimensions similar to that 
of a silicon wafer, for example, approximately 500 to 750 
micrometers in thickness and 100, 150, 200, 300, 450, or 675 
mm in diameter. 
For example, referring to FIGS. 8L and 8M a nanochannel 
delivery device 500 is shown comprising a body 501 that is 
substantially planar and has a rectangular shape with a thick-
ness "T", a length "L" that is 4 mm and a width "W" that is 3 
mm. The thickness "T" may be varied, but in certain embodi-
ments is approximately 550-700 µm, and is less than either 
length L or width W. Length L and width W define the primary 
plane of nanochannel delivery device 500. As shown in the 
figures, body 501 has an inlet surface 502 on one side and an 
outlet surface 503 on the opposite side. Inlet surface 502 and 
outlet surface 503 are generally parallel to each other and 
parallel to the primary plane of nanochannel delivery device 
500. Visible in FIG. 8M are a plurality of inlet macrochannels 
545 (only one of which is identified in the figure). FIG. 8N 
provides a perspective view of a partial cross-section of 
nanochannel delivery device 500 taken along line 8N-8N in 
FIG. 8M. The portion illustrated in FIG. 8N comprises a 
single inlet macrochannel 545 and multiple inlet microchan-
nels 540 and outlet microchannels 580. As shown in FIGS. 
8L-8N, inlet microchannels 540 and outlet microchannels 
580 are formed so that individual inlet and outlet microchan-
nels are perpendicular to the primary plane of nanochannel 
delivery device 500 (e.g., the length of the microchannels is 
measured along a line that is perpendicular to the primary 
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plane of the device). In addition, the plurality of inlet micro-
channels 540 and outlet microchannels 580 form overlapping 
arrays so that individual inlet microchannels 580 are distrib-
uted between individual outlet microchannels 580, and vice 
versa. Referring now to FIG. 8 As shown in the detailed view 
of FIG. 80, each nanochannel 505 is in direct fluid commu-
nication with an inlet microchannel 540 and an outlet micro-
channel 580. 
Referring now to FIG. 8P, a detailed section view of a 
section of nanochannel delivery device 500 is illustrated. In 
this view, three inlet nanochannels 540 are visible, along with 
a pair of outlet microchannels 580 and a pair of nanochannels 
505. As shown, nanochannel 505 comprises an inlet end 506 
and an outlet end 507. In this embodiment, a first linear axis 
508 extends between inlet end 506 and inlet surface 502. Also 
visible in FIG. 8P, a second linear axis 509 extends between 
outlet end 507 and outlet surface 503. 
Also shown in FIG. 8P, inlet microchannel 540 comprises 
a primary axis 512 and outlet microchannel 580 comprises a 
primary axis 511. As shown in this embodiment, primary axis 
511 andprimary axis 512 are perpendicular to aplane513 that 
is parallel to a substantially planar body 550 of nanochannel 
delivery device 500. In FIG. 8P, only a portion of substantially 
planar body 550 is shown. A complete view of substantially 
planar body 550 is visible in FIGS. 8L and 8M. 
Referring now to FIG. 9, specific dimensions for an exem-
plary embodiment of a nanochannel delivery device manu-
factured according to the above protocol are provided. It is 
understood that these dimensions are illustrative of the spe-
cific embodiment shown, and that other embodiments may 
incorporate different dimensions. 
Referring now to FIG. 10, a partial cross-section of 
nanochannel delivery device 500 illustrates the diffusionpath 
575 for a molecule passing through nanochannel delivery 
device 500. It is understood that nanochannel delivery device 
500 may be oriented in any direction during use. As shown in 
FIG. 10, flow path 105 requires a maximum of two changes in 
direction between the point where the molecule enters 
nanochannel delivery device 500 and the point at which the 
molecule exits nanochannel delivery device 500. For 
example, the molecule enters nanochannel delivery device 
500 and is initially located within inlet macrochannel 545. 
The molecule then enters inlet microchannel 540. In the 
embodiment shown, flow path 575 turns at a 90 degree angle 
to the right as the molecule enters the nanochannel 505 that is 
in direct fluid communication with inlet microchannel 540. 
After the molecule exits the nanochannel 505, the flow path 
turns again (this time, a 90 degree turn to the left) as it enters 
the outlet microchannel 580, which is also in direct fluid 
communication with the nanochannel 505. Therefore, flow 
path 575 requires a maximum of two changes in direction as 
the molecule diffuses through nanochannel delivery device 
500. While a molecule may undergo more than two changes 
in direction as it passes through nanochannel delivery device 
500, it is only required to make two changes in direction. 
Example 
Protocol I 
Bonded Capping Layer 
The following example is provided as an illustration of one 
non-limiting embodiment of a method of manufacturing a 
nanochannel delivery device according to Protocol I (de- 
20 
scribed above). This example is provided for illustration pur-
poses only and is not intended to limit the scope of the inven-
tion described herein. 
Processing begins with a double polished 4" SOI wafer 
5 (available from Silicon Quest), The wafer comprises a device 
layer that is 30 um thick, <100> orientation P-type, Boron 
doped, and a 1-10 Ohm-cm surface resistivity, a buried oxide 
layer that is 0.4 um thick and a handle layer that is 500 um 
thick, P-type, Boron doped, and 1-10 Ohm-cm surface resis- 
io tivity. The wafer was cleaned in a fresh Piranha solution (3:1 
98% sulfuric acid: 30% hydrogen peroxide, over 100 C) for 
10 min, and spun dried. A 50 nm pad oxide layer was then 
thermally grown on the surface. Then a 100 nm low-stress 
nitride was deposited on the pad oxide layer by low-pressure 
15 chemical vapor deposition (LPCVD). The 5 um wide 
nanochannel patterns were transferred from the photo mask 
onto the silicon nitride layer by standard photolithography 
using an EVG 620 aligner. The exposed nitride area was 
removed by CF4 RIE. 
20 	 After the photoresist was stripped, the pad oxide was 
cleaned by dipping in 1:10 HE water solution. Then the wafer 
was placed in a thermal oxide furnace to grow sacrificial 
oxide. The thickness of this sacrificial oxide determined the 
height of nanochannels, i.e. height of 
25 nanochannel-0.46 *Thickness of Oxide. In this example, a 39 
nm oxide was grown for I8 nm nanochannels. Then the 
nitride and oxide were removed in dilute HE solution. A 3 um 
thick low temperature oxide (LTO) layer was then deposited 
on the surface by LPCVD. Then the backside of wafer was 
30 protected by 3 um spun-on Futurrex negative photoresist. The 
LTO on front side was removed in a buffered oxide etch 
(BOE) solution, and the wafer was cleaned in piranha solu-
tion. 
A 500 nm LTO film was deposited on the wafer using 
35 LPCVD. The 5 umx5 um inlet microchannel patterns were 
transferred to the LTO film on the device side of wafer using 
standard lithography on an EVG 620 aligner, and LTO were 
etched using CF4 RIE. Then the 200 umx200 um inlet mac-
rochannel patterns were transferred onto the backside of the 
40 wafer, and RIE was done. 
After cleaning out the photoresist, deep silicon etching of 
inlet microchannels was done using an Oerlikon DSE etcher. 
The etching was stopped on the buried oxide layer. The wafer 
was flipped over, and attached onto a handle wafer using 
45 thermal grease (Al Technology). The 190 umx190 um inlet 
macrochannels were then etched on the Oerlikon DSE etcher, 
and stopped on the oxide layer. FIG. 11 shows a SEM image 
of deep etched 190 um openings. The wafer was detached 
from the handle wafer, and cleaned. The wafer was dipped in 
5o BOE for 5 min to open the buried oxide layer, and spun dried. 
Then mask LTO films on both sides of wafer were removed in 
HE water solution. 
A 500 um thick double side polished Pyrex 7740 glass 
wafer was bonded onto the silicon substrate as a nanochannel 
55 cap by anodic bonding using an EVG 520 bonder. The anodic 
binding was performed at 800 volts, and 325° C. for 10 min. 
FIG. 12 shows an optical image of the bonded wafer. The 
bonded wafer pair was adhered on a wafer holder using wax, 
and backlapping was applied to thin the glass down to 30 um, 
6o and then CMP polished to a final thickness of 5-10 um (by 
Valley Design Corp). 
FIG. 13 shows an optical image of the front surface after 
polishing. The contrast indicates that nanochannels are open. 
The 5 umx5 um outlet microchannels were formed by CF4/ 
65 Ar RIE using Ni film as mask layer. To do so, a copper seed 
layer was firstly deposited on the glass surface. The 5 umx5 
um outlet microchannel patterns were transferred to the cop- 
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per film using standard lithography on an EVG 620 aligner, 
and were wet etched. Then Ni was electroplated onto the 
patterned copper film. The CF4/Ar RIE was used to etch the 
inlet microchannels into the glass film to reach the silicon 
surface. After stripping the mask layer, the wafer was cleaned, 
and diced using DAD321 Dicing Saw (Disco). The fabricated 
devices are 6 mmx6 mm overall dimension. There are 161 in 
total 190 umx190 um openings arranged in a 3.6 mm diam-
eter circle. Each such opening is connected to 501 in total 5 
umx5 um inlet channels, and the inlet channels are connected 
to nanochannel and outlet channels. 
Example 
Protocol 3 
Monolithically Fabricated Capping Layer 
The following example is provided as an illustration of one 
non-limiting embodiment of a method of manufacturing a 
nanochannel delivery device according to Protocol 3 (de-
scribed above). This example is provided for illustration pur-
poses only and is not intended to limit the scope of the inven-
tion described herein. 
Processing begins with a double-side polished Silicon On 
Insulator (SOI) wafer using a 690 um thick base wafer with a 
top silicon layer thickness of 30 um and a buried oxide thick-
ness of 2 um. This wafer is cleaned with a piranha solution 
(3:198% Sulfuric acid: 30% Hydrogen peroxide, over 100 C) 
to remove any organic and metal contamination. A smooth 
(typically <5 A rms), uniform (typically <2% non-unifor-
mity,) tungsten metal layer is sputtered on this wafer, using a 
physical vapor deposition (PVD) process at a temperature of 
100 C. The thickness of this tungsten layer is selected to be the 
height of the nanochannel layer, for example 5 mu. 
The nanochannel space layer is then covered by a plasma 
enhanced chemical vapor deposition (PECVD) silicon nitride 
(" S1NI ") with low stress (380 C, appropriate stoichiometry), 
with a target thickness of 500 nm and a non-uniformity of less 
than 2%. Positive resist is then spun on, with a thickness of 2 
um. The inlet microchannels are exposed in this resist, with 
the sizes varying from 1 um to over 5 um, as needed. Using 
this resist, the applied silicon nitride is etched through, along 
withtungsten, using a conventional C4F8 etch chemistry with 
appropriate plasma powers, and other reactive and inert 
gases. 
The etch in this process is timed to be deep enough that it 
goes through the tungsten layer also, which takes a few min-
utes. Another etch is performed, still using the resist as the 
mask, to etch a deep via in the silicon that is deep enough to 
go into the buried oxide. A 5 dep/5 etch per cycle Bosch etch 
is used in this step since the etch automatically terminates at, 
and is highly selective to, the buried oxide. A small overetch 
of 10-20% of the most critical structure is provided to com-
pensate for the non-uniformity of the process. The remaining 
resist is then removed using an oxygen plasma and the wafers 
are additionally cleaned of all polymer residues using an 
appropriate wet chemistry FIG. 14 presents an example of a 
device at this stage of process. 
The next module consists of filling or capping these inlet 
microchannels. This can be accomplished by plugging the 
inlets with copper. A TiN barrier layer is deposited by sputter, 
with a thickness of 300 A. A copper seed layer, with a nominal 
thickness of about 4000A is deposited through a PVD sputter 
process. A low current (2 A, 10-15 minutes) electroplating 
process is used to fill or plug the inlet microchannels. The 
excess copper overburden is then polished away using a pad/ 
22 
slurry combination, under moderate pressure/speed (2-4 psi, 
30-90 rpm) process. In this same process, the TiN in the 
non-microchannel area (field) is also completely removed. 
Finally, the inlet microchannel process is hardened with a 
5 short bake anneal at 150-250 C, for about 30 minutes, and the 
surface is cleaned. FIG. 15 presents a top view of the device 
after filling with copper. 
A thin silicon nitride ("SiN2") layer of about 50 mn is 
deposited by PECVD to cap the copper. The nanochannel 
10 lines are then exposed in resist (1.3 um) using photolithogra-
phy and the silicon nitride (S1NI as well as SiN2) layers are 
etched, along with the tungsten nanochannel material, with 
the etch proceeding a few tens of nanometers into the silicon. 
15 A thicker, tensile silicon nitride ("SiN3") is then deposited, 
of a thickness of about 1-1.5 um. The tensile stress of this 
layer is chosen so as to make the overall dielectric stack 
slightly tensile by about 20 MPa. The outlet microchannels 
are then exposed on a resist layer (of nominal thickness 2 um) 
20 and a further etch of all silicon nitride layers (S1NI, SiN2, 
SiN3) along with the W nanochannel layer are etched so that 
the bottom of the outlet microchannels end in the device 
silicon. The resist is stripped after this stage. FIG. 16 presents 
a cross-section of a device at this stage of processing. 
25 An appropriate protection layer is applied to the surface 
Ti/TiN (250/300A), Tungsten (5000 A) followed by Phospho 
silicate Glass (PSG) of thickness of 1 um, which can be used 
as both an HE protectant as well as a surface protectant. The 
wafer is then turned upside down and a thick resist (10 um) is 
30 spun on. Using the front side alignment marks, macrochan-
nels are exposed on the backside. The macrochannels are 
etched all the way through the wafer (about 700 um) using a 
Bosch DRIE process. This process lands on the buried oxide, 
which forms an effective etch stop. FIG. 17 presents a cross- 
35 section of a test device at this stage of processing. This buried 
oxide is then removed by a plasma etch. 
A series of wet etches are done to remove all the sacrificial 
materials. A short buffered HE etch, for about 5 minutes, is 
done to remove any residual oxide (of the buried oxide), as 
40 well as to remove the PSG layer. The wafers are then wet-
etched in an SC-1 solution (hot Ammonium hydroxide 
hydrogen peroxide mixture) for about 10 minutes to remove 
the TiN barrier at the top surface as well as at the bottom of the 
inlet microchannels. The wafers are subjected to a piranha 
45 etch for about 20 minutes to remove the copper in the inlet 
microchannels. This is followed by another SC-1 etch to 
remove all the TiN from the sidewalls of the inlet microchan-
nels. Finally, the Tungsten is removed from the nanochannels 
by placing the wafers in wafer hydrogen peroxide for 2 hours, 
50 followed by a rinse with DI water. The wafers are then cleaned 
with Iso-Propyl Alcohol (IPA) to displace the water with IPA, 
and the wafers are allowed to dry. 
Material Selection 
Regardless of the protocol used to manufacture the 
55 nanochannel delivery device, the materials used during the 
manufacturing process should be selected to successfully 
remove sacrificial materials while leaving the non-sacrificial 
materials. As shown in FIG. 18, the selection of a nanochan-
nel "placeholder" (e.g., the sacrificial material used to fill the 
60 space of the nanochannel) and nanochannel "ceiling" and 
"floor" materials (e.g., the substrate and capping layers) 
should be coordinated with the selection of a solvent or 
etchant. Examples of suitable solvents and etchants that can 
be used to remove sacrificial materials while leaving the 
65 substrate and capping layers are shown in FIG. 18. It is 
understood that other combinations of materials may be uti-
lized as well. 
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Post Wafer Processing 
During post wafer processing, each wafer is attached to a 
tape-ring with an adhesive tape. A UV release tape is pre-
ferred since it has better adhesion. Since both surfaces of the 
wafer have critical device structures, UV tape is attached to 5 
both top and bottom surfaces. The wafers are then diced into 
individual die and cleaned. The tapeframe is then exposed to 
a UV light source to decrease the adhesion of the tape to the 
surface. The dice are individually picked and placed into a 
bare-die holder using an automated pick and place sorter tool. io 
The tape on the top surface of the die is subsequently peeled 
off manually. The dice are then individually placed in a final 
clean container and cleaned with acetone with a final rinse of 
IPA to promote channel drying. A die is attached by epoxy or 
other fixing method to a capsule mating surface. 15 
Capsule Configurations 
Referring now to FIGS. 19 and 20, nanochannel delivery 
device 500 may form part of a larger assembly, e.g., a capsule 
600 that may be used to administer drugs or other therapeutic 
agents to a patient. FIG. 19 shows a detailed view of one end 20 
of capsule 600 in an exploded view, while FIG. 20 illustrates 
an assembled view of capsule 600. It is understood that in 
other embodiments, nanochannel delivery device 500 may be 
used in other applications where it is desired to precisely 
control the diffusion or passage of small amounts of any 25 
substance. 
In the embodiment shown in FIGS. 19 and 20, capsule 600 
comprises a generally cylindrical body 620 having an end 
portion 630 configured to receive a first cap 610 and a second 
cap 625. In this embodiment, nanochannel delivery device 30 
500 is installed in a plane that is perpendicular to the primary 
axis of capsule 600 (e.g., an axis that is parallel to the length 
of cylindrical body 620 and concentric with cylindrical body 
620). End portion 630 also comprises a recessed portion 640 
configured to receive nanochannel delivery device 500. In 35 
certain embodiments, a glue or other boding agent may be 
used to secure nanochannel delivery device 500 in recessed 
portion 640. When assembled, nanochannel delivery device 
500 can be inserted into recessed portion 640, and first cap 
610 may be fitted onto end portion 630. 40 
During use, drugs (or any other substance administered via 
capsule 600) canpass from cylindrical body 620 to nanochan-
nel delivery device via an inner volume 650 contained within 
cylindrical body 620. After diffusing through nanochannel 
delivery device 500 and into first cap 610, the administered 45 
substances can exit cap 610 via exit ports 615. In exemplary 
embodiments, the dimensions of exit ports 615 (and other 
aspects of capsule 610, suchas innervolume 650 and cap 610) 
are large enough so that these features do not restrict the 
diffusion of the administered substance from capsule 600. As 50 
a result, the diffusion of the administered substance can be 
more precisely controlled by selecting the dimensions of 
nanochannel delivery device 500, particularly the dimensions 
of nanochannels 505. Cap 610 may also provide dimensional 
rigidity and protect nanochannel delivery device 500 from 55 
mechanical damage and the incursion of biological tissue 
structures after implantation. 
In certain embodiments, inner volume 650 is configured to 
minimize capture points for air bubbles. For example, inner 
volume 650 may comprise radiused corners and surfaces that 60 
are not angled in a manner (when capsule 600 is installed) 
which could trap air bubbles. 
Referring now to FIGS. 21 and 22, capsule 700 is similar to 
the previously-described capsule 600. However, in this 
embodiment capsule 700 is fitted with a septum 760 on the 65 
end of cylindrical body 720 that is distal from end portion 
630. Septum 760 comprises a self-sealing material (e.g., sili- 
cone rubber) that permits injection of a therapeutic agent into 
inner volume 750 of cylindrical body 720. In certain embodi-
ments, a therapeutic agent can be injected with a hypodermic 
needle just prior to implantation of capsule 700. 
Referring now to FIG. 23, a capsule 800 comprises com-
ponents equivalent to previously-described embodiments. 
However, this embodiment comprises a cap 825 that covers 
septum 860. Cap 825 may comprise an orifice (not visible in 
the perspective view of FIG. 21) configured to guide a needle 
or other device used to penetrate septum 860 and inject a 
therapeutic agent into inner volume 850 of cylindrical body 
820. 
Referring now to FIG. 24, a capsule 900 comprises a cylin-
drical body 922 coupled to a separate end component 935 and 
a cap 925. In this embodiment, cylindrical body 922 can be 
replaced with another cylindrical body having a different 
length in order to vary the internal volume of capsule 900 (and 
the amount of therapeutic agent that capsule 900 can contain). 
Similar to previous embodiments, end component 935 com-
prises an end portion 930 configured to receive cap 910. End 
component 935 also comprises a recessed portion 940 con-
figured to receive nanochannel delivery device 500. 
Referring now to FIGS. 25 and 26, a capsule 1000 com-
prises a disc-shaped body 1020 with a cap 1010 comprising a 
series of exit ports 1015. In this embodiment, disc-shaped 
body 1020 comprises a septum 1060 through which a thera-
peutic agent may be injected. As shown in the exploded view 
of FIG. 26, supports 1050 can be used to hold nanochannel 
delivery device 500 proximal to exit ports 1015. In this man-
ner, a therapeutic agent contained within capsule 1000 is 
forced to pass through nanochannel delivery device 500 
proximal before exiting capsule 1000. 
In the embodiment shown in FIGS. 27 and 28, a capsule 
1100 comprises a rectangular planar surface 1121 and an 
arched surface 1120. Capsule 1100 also comprises a closed 
end 1125 and a septum 1160 that can be inserted into an open 
end 1161. In the embodiment shown, septum 1160 covers the 
entire open end 1161. In other embodiments, a septum may 
cover part of an open end, and a cap may cover the remaining 
portions. Similar to previously-described embodiments, sep-
tum 1160 is self-sealing and can be punctured with a needle to 
insert a therapeutic agent. Capsule 1100 also comprises a first 
recessed portion 1140 configured to receive nanochannel 
delivery device 500, and a second recessed portion 1130 
configured to receive a cap 1110 comprising exit ports 1115. 
An aperture 1135 extends through recessed portion 1140 into 
an inner volume 1150 bounded by rectangular planar surface 
1121, arched surface 1120, closed end 1125 and septum 1160. 
In this embodiment, a therapeutic agent can be contained 
within inner volume 1150 and dispensed through aperture 
1135, nanochannel delivery device 500, and exit ports 1115. 
Referring now to FIG. 29, another embodiment of a cap-
sule 1200 is generally equivalent to capsule 1100, but com-
prises features that accommodate two nanochannel delivery 
devices (not shown). In this embodiment, capsule 1200 com-
prises a rectangular planar surface 1221, arched surface 1220, 
closed end 1225 and septum 1260. Capsule 1200 also com-
prises a pair of first recessed portion 1240 each configured to 
receive nanochannel delivery device (not shown), and a sec-
ond pair of recessed portions 1230 each configured to receive 
a cap with exit ports (not shown). Each recessed portion 1240 
comprises an aperture 1235 that provides fluid communica-
tion between inner volume 1250 and the environment sur-
rounding capsule 1200. 
In certain embodiments, inner volume 1250 comprises 
separate, internal reservoirs in which each reservoir is in fluid 
communication with a single aperture 1235. The internal 
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reservoirs may be separated by inner walls within aperture 	 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 
1235. In such embodiments, each reservoir may be filled with 
	
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 
a separate therapeutic agent. Each nanochannel device can be 	 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 
configured to provide the preferred dosage of each individual 
	
116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 
therapeutic agent. 	 5 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 
Referring now to FIG. 30, another embodiment of a cap- 	 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 
sule 1300 is shown in an installed position so that it partially 	 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 
extends beneath an epidermal surface 1301 of a patient into 	 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 
which capsule 1300 has been inserted. Capsule 1300 com- 	 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 
prises multiple covers 1310 with exit ports 1315. Beneath io 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199 or 
each cover 1310, a nanochannel delivery device is inserted 
	
200 mm. In other embodiments, the capsule may have a 
over an aperture that is in fluid communication with an inner 	 length greater than 200 mm. 
volume of capsule 1300 (similar to the embodiments 	 It is noted that the various embodiments of capsules 
described in FIGS. 27 -29). The inner volume of capsule 1300 	 described in this disclosure comprise a cross-section that is 
may be divided into separate compartments so that each 15 nominally constant along the length of the capsule. Such an 
nanochannel delivery device can be used to administer a 	 optional configuration can facilitate sliding removal from a 
specific and distinct therapeutic agent. Capsule 1300 also 	 surgical site within the body without damage to surrounding 
comprises an anchor member 1305 configured to serve as a 	 tissue. 
point at which a suture (not shown) can be attached to capsule 	 In exemplary embodiments a capsule may comprise suit- 
1300 when it is installed. Anchor member 1305 may also be 2o able materials such as stainless steel, titanium, polyethere- 
coupled to a string or other device (not shown) used to remove 	 therkeytone, polysulfone, and other plastics and metals. In 
or retrieve capsule 1300. 	 certain embodiments, a capsule may comprise coating(s) on 
Referring now to FIG. 31, another embodiment of a cap- 	 the interior to provide an optimal environment for a therapeu- 
sule 1400 is shown. This capsule is a minimal covering of the 	 tic substance and/or coating(s) on the exterior to prevent 
back and sides of the nanochannel device, such that the "res-  25 deleterious tissue encapsulation. In specific embodiments, 
ervoir" for a contained drug is limited to the volume of the 	 the capsule may comprise color coding to indicate the model 
macrochannels on the back of the chip (e.g., the nanochannel 	 of the capsule or a particular characteristic (e.g., the thera- 
delivery device), which is about 4.5 mm 3 for the embodiment 	 peutic agent, rate of administering the agent, the capacity of 
shown in FIG. 8K. This embodiment can be made particularly 	 the capsule, etc.). In certain embodiments, a capsule may 
small, for example 2 mmx2 mmx0.5 mm, and is, therefore, 30 comprise a translucent or transparent portion or component 
especially suited for implantation with very high potency 	 (e.g. a cap) to facilitate observation of the quantity of thera- 
drugs into sensitive locations, e.g., glaucoma medication into 	 peutic agent contained within the capsule. For example, a 
the inner portion of the eye. 	 translucent or transparent cap covering the nanochannel 
Exemplary embodiments of the previously-described cap- 	 delivery device can allow a person to confirm the capsule is 
sules can be sized so that the capsule may be implanted 35 full by orienting the capsule so that the nanochannel delivery 
subcutaneously. In specific embodiments, the capsule may 	 device is positioned towards the top of the capsule. A needle 
have a diameter of 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 	 (or other loading device) can then penetrate the septum and 
1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 	 the therapeutic agent can be injected into the capsule. When 
2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 	 liquid appears on the top of the nanochannel delivery device 
4.3,4.4,4.5,4.6,4.7,4.8,4.9,5.0,6.0,7.0,8.0,9.0, 10.0, 11.0, 40 (as viewed through the cap), the person filling the capsule will 
12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0 or 20.0 mm. In 	 have an indication that the capsule is full. 
other embodiments, the capsule may be greater than 20.0 mm 	 In exemplary embodiments, a capsule may be used to 
in diameter. 	 administer one or more of the following substances: adrener- 
In certain embodiments, the capsule may have a thickness 	 gic agent; adrenocortical steroid; adrenocortical suppressant; 
of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9,1.0,1.1,1.2,1.3,1.4, 45 aldosterone; alkylating agent; antagonist; amino acid; ana- 
1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 	 bolic; analeptic; analgesic; anesthetic; anorexogenic; anti- 
2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 	 acne agent; anti-adrenergic; anti-allergic; anti-alopecia 
4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 	 agent; anti-amebic; anti-anemic; anti-anginal; antiangio- 
5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 	 genic, anti-anxiety; anti-arthritic; anti-asthmatic; anti-athero- 
7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 50 sclerotic; antibacterial; antibiotic; anticancer; anticholin- 
8. 5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9. 8, 	 ergic; 	 anticoagulant 	 anticonvulsant; 	 antidepressant; 
9.9 or 10.0 mm. In other embodiments, the capsule may have 	 antidiabetic; antidiarrheal; antidiuretic; anti-dyskinetic; anti- 
a thickness greater than 10.0 mm. 	 emetic; anti-epileptic; antifibrinolytic; antifungal; anti-hem- 
In specific embodiments, a capsule may have a width of 1, 	 orrhagic; antihistamine; anti-hypercalcemic, anti-hypercho- 
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 55 lesterolaemic; anti-hyperlipidaemic; anti-hypertensive; anti- 
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 	 hypertriglyceridemic; anti-hypotensive; anti-infective; anti- 
38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 	 inflammatory; anti-ischemic; antimicrobial; antimigraine; 
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 	 antimitotic; antimycotic; anti-nauseant; anti-neoplastic; anti- 
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 	 neutropenic; anti-obesity agent; anti -o steoporotic, antipara- 
89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 mm. In other 60 sitic; antiproliferative; antipsychotic; antiretroviral; anti-re- 
embodiments, the capsule may have a width greater than 100 	 sorptives; anti-rheumatic; anti-seborrheic; antisecretory; 
mm. 	 antispasmodic; antisclerotic; antithrombotic; antitumor; anti- 
In specific embodiments, a capsule may have a length of 1, 	 ulcerative; antiviral; appetite suppressant bisphosphonate; 
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 	 blood glucose regulator; bronchodilator; cardiovascular 
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 65 agent; central nervous system agent; contraceptive; cholin- 
38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 	 ergic; concentration aid; depressant; diagnostic aid; diuretic; 
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 	 DNA-containing agent, dopaminergic agent; estrogen recep- 
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for agonise fertility agent; fibrinolytic; fluorescent agent; free 	 histrelin acetate, Human growth hormone, Hydralazine 
oxygen radical scavenger; gastric acid supressant; gas- 	 hydrochloride, Hydrocodone bitartrate, Hydroxyurea, 
trointestinal motility effector; glucocorticoid; glutamatergic 	 Hydroxyzine hydrochloride, Ibandronate, Imatinib, Imigluc- 
agent; hair growth stimulant; hemostatic; histamine H2 	 erase, Imipenem, imiquimod, Indinavir sulfate, infliximab, 
receptor antagonist; hormone; hypo cholesterolemic; 5 Interferon beta-la, Ipratropium, Irbesartan, Irinotecan, Iso- 
hypoglycemic; hypolipidemic; hypotensive; imaging agent; 	 niazid, Isosorbide moninitrate, ixabepilone, ketamine, keto- 
immunizing agent; immunomodulator; immunostimulane 	 conazole, Ketorolac, Lactobionate, Lamivudine, Lamivu- 
immunosuppressant; interleukin, keratolytic; LHRH agonise 	 dine, Lamotrigine, lanreotide acetate, Lansoprazole, 
mood regulator; mucolytic; mydriatic; nasal decongestant; 	 lapatinib, laropiprane Latanoprose Letrozole, Leuprolide, 
neuromuscular blocking agent; neuroprotective; NMDA io Levalbuterol, Levamisole hydrochloride, Levetiracetam, 
antagonist; non-hormonal sterol derivative; nootropic agent; 	 levocetirizine dihydrochloride, levodopa, Levofloxacin, 
parasympathomimetic agent; plasminogen activator; platelet 	 levonorgestrel, Levothyroxine, levothyroxine sodium, 
activating factor antagonist; platelet aggregation inhibitor; 	 Lidocaine, Linezolid, Lisdexamfetamine Dimesylate, Lisi- 
platinum-containing agent, psychotropic; radioactive agent; 	 nopril, Lispro insulin, Lopinavir, Loratadine, lorazepam, 
raf antagonist, RNA-containing agent, scabicide; sclerosing 15 Losartan potassium, maraviroc, Marinol, meclizine hydro- 
agent; sedative; sedative-hypnotic; selective adenosine Al 	 chloride, Meloxicam, Memantine, Meropenem, metaxalone, 
antagonist; selective estrogen receptor modulator, serotonin 	 metformin, Metformin Hydrochloride, methadone, methoxy 
antagonist; serotonininhibitor; serotonin receptor antagonist; 	 polyethylene glycol-epoetin beta, Methylphenidate, Meth- 
steroid; stimulant; thrombic agent; thyroid hormone; thyroid 	 ylphenidate hydrochloride, Metoprolol, Metoprolol tartrate, 
inhibitor; thyromimetic; tranquilizer; vasoconstrictor; 20 metronidazole, Metronidazole, miglitol, Minocycline, 
vasodilator; wound healing agent; xanthine oxidase inhibitor; 	 Minocycline hydrochloride, mirtazepine, Modafinil, 
and the like; Abacavir, Abacavir sulfate, abatacepe Acarbose, 	 Mometasone, montelukast, Montelukast sodium, Morphine, 
Acetaminophen, Aciclovir, Adalimumab, Adapalene, Alen- 	 Moxifloxacin, Mycophenolate mofetil, Naloxone, Naproxen 
dronate, Alendronate sodium, Alfuzosin, aliskiren, allopu- 	 sodium, natalizumab, Neostigmine bromide, Niacin, Nicoti- 
rinol, alvimopan, ambrisentan, Aminocaproic acid, Amitrip-  25 namide, Nifedipine, Nifurtimox, nilotinib hydrochloride 
tyline hydrochloride, amlodipine, amlodipine besylate, 	 monohydrate, nitrofurantoin, Nortriptyline hydrochloride, 
amoxicillin, amoxicilline, Amphetamine, Anastrozole, Arip- 	 nystatin, olanzapine, Olanzepine, Olmesartan, olmesartan 
iprazole, annodafinil, Atazanavir, atenolol, Atomoxetine, 	 medoxomil, olopatadine hydrochloride, Omalizumab, 
atorvastatin calcium, atorvastatin, Atropine sulfate, Azelas- 	 Omega-3 acid ethyl esters, Omeprazole, Ondansetron, Orl- 
tine, azithromycin, Balsalazide, Benazepril, bendamustine 30 istae Oseltamivir, Oxaliplatin, Oxcarbazepine, Oxybytynin 
hydrochloride, Benzepril hydrochloride, bevacizumab, 	 chloride, oxycodone hydrochloride, Paclitaxel, Palivizumab, 
Bicalutamide, Bimatoprose Bisoprolol, Bisoprolol fumarate, 	 Pantoprazole, paracetamol, Paroxetine, paroxetine hydro- 
Bosentan, Botulin toxin, Budesonide, Buformin, Buprenor- 	 chloride, Pegylated interferon alfa-2a, Pemetrexed, Penicil- 
phine, Bupropion, bupropion hydrobromide, Bupropion 	 lamine, Penicillin V potassium, Phenformin, Phenyloin 
Hydrochloride, Cabergoline, Calcipotriol, calcitriol, cande-  35 sodium, Pioglitazone, Piperacillin, Potassium chloride, 
sartan cilexetil, Capecitabine, Captopril, carbidopa, cariso- 	 Pramipexole, Pravastatin, Pravastatin sodium, prednisolone 
prodol, Carvedilol, Caspofungin, Cefdinir, Cefoperazone, 	 quetiapine fumerate, Pregabalin, Primaquine phosphate, 
Cefotiam, cefprozil, Cefuroxime, Celecoxib, cephalaxin, 	 Progesterone, Promethazine, Promethazine hydrochloride, 
Certolizumab Pegol, Cetirizine, Cetrizine hydrochloride, 	 Proponolol hydrochloride, Propoxyphene hydrochloride, 
Cetuximab, Chlorpromazine hydrochloride, Chlorphe-  40 pseudoephedrine, Pseudophedrine hydrochloride, Pyri- 
niramine maleate, ciclesonide, Cilastatin, cimetidine, Cina- 	 dostigmine bromide, Pyridoxine hydrochloride, Quetiapine, 
calcee Ciprofloxacin, citalopram hydrobromide, Clarithro- 	 quetiapine fumarate, Quinapril hydrochloride, Rabeprazole, 
mycin, 	 Clindamycin, 	 Clindamycin, 	 clindamycin 	 raloxifene, raltegravir, Ramipril, Ranitidine, Ranitidine 
hydrochloride, Clomipramine hydrochloride, Clonidine 	 hydrochloride, Recombinant factor VIII, retapamulin, 
hydrochloride, clopidogrel, Clopidogrel bisulfate, Cloxacil-  45 Rimonabane Risedronate, Risedronate sodium, risperidone, 
lin Sodium, Co-Amoxiclav, Codeine phosphate, Colchicines, 	 Ritonavir, rituximab, Rivastigmine, rivastigmine tartrate, 
Colesevelam, cyclobenzaprine hydrochloride, Cyclophos- 	 Rizatriptan, Ropinirole, rosiglitazone, Rosiglitazone male- 
phamide, Cyclosporine, darbepoetin alfa, Darifenacin, 	 ate, Rosuvastatin, Rotavirus vaccine, rotigotine, Salbutamol, 
DCRM 197 protein, Desloratadine, desloratidine, Desmo- 	 Salbutamol sulfate, salmeterol, sapropterin dihydrochloride, 
pressin 	 sulfate, 	 Desoximetasone, 	 dexamethasone, 50 Sertraline, sertraline hydrochloride, Sevelamer, Sevoflurane, 
Diclofenac, Diethylcarbamazine citrate, difluprednate, 	 Sildenafil, sildenafil citrate, simvastatin, Simvastatin, Sita- 
diphenhydramine, Dipyridamole, DL-methionine, Doc- 	 gliptin, Sodium valproate, Solifenacin, Somatostatin, Soma- 
etaxel, Donepezil, doripenem, Dorzolamide, Doxazosin, 	 tropin, 	 Stavudine, 	 Sulfomethoxazole, 	 Sumatriptan, 
doxazosin mesylate, doxycydine, Drospirenone, Duloxetine, 	 Sumatriptan succinate, Tacrolimus, Tadalafil, tamoxifen cit- 
Dutasteride, eculizumab, Efavirenz, Emtricitabine, Enala-  55 rate, Tamsulosin, tamsulosin hydrochloride, Tegaserod, 
pril, enalapril maleate, Enoxaparin Sodium, Eprosartan, Erlo- 	 Telmisartan, temazepam, Temozolomide, temsirolimus, 
tinib, Erythromycin, Erythropoetin, Escitalopram, esomepra- 	 Tenofovir, Terazosin Hydrochloride, Terbinafine, Teri- 
zole, estradiol, Estrogen, Eszopiclone, etanercepe 	 paratide, testosterone, Tetracycline hydrochloride, Thalido- 
Ethembutol hydrochloride, Ethosuximide, ethynl estradiol, 	 mide, thymopentin, Timolol meleate, Tiotropium, tipranavir, 
etonogestrel, etoricoxib, etravirine, Exenatide, Ezetimibe, 6o Tolterodine, tolterodine tartrate, topiramate, topotecan, Tra- 
Ezetimibe, Factor VII, famotidine, Famotidine, Fenofibrate, 	 madol, Tramodol hydrochloride, trastuzumab, trazodone 
Fenofibrate, Fentanyl, Fentanyl citrate, Ferrous sulfate, Fex- 	 hydrochloride, trimethoprim, Valaciclovir, Valacyclovir 
ofenadine, fexofenadine hydrochloride, Filgrastim, Finas- 	 hydrochloride, Valproate semisodium, valsartan, Vancomy- 
teride, fluconazole, Fluoxetine hydrochloride, Fluticasone, 	 cin, Vardenafil, Varenicline, venlafaxine, Venlafaxine hydro- 
Fluvastatin, folic acid, Follitropin alfa, Follitropin beta, For-  65 chloride, Verapamil Hydrochloride, vildagliptin, Voglibose, 
moterol, Fosinopril sodium, Gabapentin, Gabapentin, Gem- 	 Voriconazole, Wafarin sodium acetylsalicylic acid, Zaleplon, 
citabine, glargine insulin, Glatiramer, glimepride, Goserelin, 	 Zidovudine, Ziprasidone, Zoledronate, Zolpidem, or phar- 
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maceutically acceptable salts thereof; 16-alpha fluoroestra- 	 Aprindine, Aprindine Hydrochloride, aprosulate sodium, 
diol, 17-alpha dihydroequilenin, 17-alpha estradiol, 17-beta 	 Aprotinin, Aptazapine Maleate, aptiganel, apurinic acid, apu- 
estradiol, 17-hydroxyprogesterone, 1-dodecpyrrolidinone, 	 rinic acid, aranidipine, Aranotin, Arbaprostil, arbekicin, arbi- 
22-oxacalcitriol, 3-isobutyl-gammabutyric acid, 6-fluorour- 	 dol, Arbutamine Hydrochloride, Arclofenin, Ardeparin 
sodeoxycholic acid, 7-methoxytacrine, Abacavir, Abacavir 5 Sodium, argatroban, Arginine, Argipressin Tannate, Aril- 
sulfate, Abamectin, abanoquil, abatacept, abecarnil, abirater- 	 done, Aripiprazole, armodafinil, arotinolol, Arpinocid, Arte- 
one, Ablukast, Ablukast Sodium, Acadesine, acamprosate, 	 flene, Artilide Fumarate, asimadoline, aspalatone, Asparagi- 
Acarbose, Acebutolol, Acecamide Hydrochloride, Aceclid- 	 nase, Aspartic Acid, Aspartocin, asperfuran, Aspirin, 
ine, aceclofenae, Acedapsone, Acedapsone, Aceglutamide 	 aspoxicillin, Asprelin, Astemizole, Astromicin Sulfate, asu- 
Aluminum, Acemannan, Acetaminophen, Acetazolamide, io lacrine, atamestane, Atazanavir, Atenolol, atevirdine, Ati- 
Acetohexamide, Acetohydroxamic Acid, acetomepregenol, 	 pamezole, Atiprosin Maleate, Atolide, Atomoxetine, atorvas- 
Acetophenazine Maleate, Acetosulfone Sodium, Acetylcho- 	 tatin, Atorvastatin Calcium, Atosiban, Atovaquone, atpenin 
line Chloride, Acetylcysteine, acetyl-L-carnitine, acetyl- 	 B, Atracurium Besylate, atrimustine, atrinositol, Atropine, 
methadol, Aciclovir, Acifran, acipimox, acitemate, Acitretin, 	 Atropine sulfate, Auranofin, aureobasidin A, Aurothioglu- 
Acivicin, Aclarubicin, aclatonium, Acodazole Hydrochlo-  15 cose, Avilamycin, Avoparcin, Avridine, Axid, axinastatin 1, 
ride, aconiazide, Acrisorcin, Acrivastine, Acronine, Actiso- 	 axinastatin 2, axinastatin 3, Azabon, Azacitidinie, Azaclo- 
mide, Actodigin, Acyclovir, acylfulvene, Adatanserin Hydro- 	 rzine Hydrochloride, Azaconazole, azadirachtine, Azalanstat 
chloride, adafenoxate, Adalimumab, Adapalene, adatanserin, 	 Dihydrochloride, Azaloxan Fumarate, Azanator Maleate, 
adecypenol, adecypenol, Adefovir, adelmidrol, ademetion- 	 Azanidazole, Azaperone, Azaribine, Azaserine, azasetron, 
ine, Adenosine, Adinazolam, Adipheinine Hydrochloride, 20 Azatadine Maleate, Azathioprine, Azathioprine Sodium, aza- 
adiposin, Adozelesin, adrafinil, Adrenalone, Aiclometasone 	 toxin, azatyrosine, azelaic acid, Azelastine, azelnidipine, 
Dipropionate, airbutamine, alacepril, Alamecin, Alanine, 	 Azepindole, Azetepa, azimilide, Azithromycin, Azlocillin, 
Alaproclate, alaptide, Albendazole, albolabrin, Albuterol, 	 Azolimine, 	 Azosemide, 	 Azotomycin, 	 Aztreonam, 
Alclofenae, Alcloxa, aldecalmycin, Aldesleukin, Aldioxa, 	 Azumolene Sodium, Bacampicillin Hydrochloride, baccatin 
Aletamine Hydrochloride, Alendronate, Alendronate 25 III, Bacitracin, Baclofen, bacosideA, bacoside B, bactobola- 
Sodium, alendronic acid, alentemol, Alentemol Hydrobro- 	 mine, balanol, balazipone, balhimycin, balofloxacin, bal- 
mide, Aleuronium Chloride, Alexidine, alfacalcidol, Alfenta- 	 salazide, Bambermycins, bambuterol, Bamethan Sulfate, 
nil Hydrochloride, alfuzosin, Algestone Acetonide, algluc- 	 Bamifylline Hydrochloride, Bamidazole, baohuoside 1, Bar- 
erase, Aliflurane, alinastine, Alipamide, aliskiren, Allantoin, 	 mastine, barnidipine, Basic, Basifungin, Batanopride Hydro- 
Allobarbital, Allopurinol, Alonimid, alosetron, Alosetron 30 chloride, batebulast, Batelapine Maleate, Batimastat, beau 
Hydrochloride, Alovudine, Alpertine, alpha-idosone, Alpi- 	 vericin, Becanthone Hydrochloride, becaplermin, beclicona- 
dem, Alprazolam, Alprenolol Hydrochloride, Alprenoxime 	 zole, Beclomethasone Dipropionate, befloxatone, Beinser- 
Hydrochloride, Alprostadil, Alrestatin Sodium, Altanserin 	 azide, Belfosdil, Belladonna, Beloxamide, Bemesetron, 
Tartrate, Alteplase, Althiazide, Altretamine, altromycin B, 	 Bemitradine, Bemoradan, Benapryzine Hydrochloride, 
Alverinc Citrate, alvimopan, Alvircept Sudotox, Amadinone 35 Benazepril, Benazepril Hydrochloride, Benazeprilat, Benda 
Acetate, Amantadine Hydrochloride, ambamustine, Ambo- 	 calol Mesylate, bendamustine hydrochloride, Bendazac, 
mycin, ambrisentan, Ambruticin, Ambuphylline, Ambuside, 	 Bendroflumethiazide, benflumetol, benidipine, Benorterone, 
Amcinafal, Amcinonide, Amdinocillin, Amdinocillin Piv- 	 Benoxaprofen, Benoxaprofen, Benoxinate Hydrochloride, 
oxil, Amedalin Hydrochloride, amelometasone, Ameltolide, 	 Benperidol, Bentazepam, Bentiromide, Benurestat, Benzbro- 
Amesergide, Ametantrone Acetate, amezinium metilsulfate, 40 marone, Benzepril hydrochloride, Benzethonium Chloride, 
amfebutamone, Amfenac Sodium, Amfiutizole, Amicycline, 	 Benzetimide Hydrochloride, Benzilonium Bromide, Benzin- 
Amidephrine Mesylate, amidox, Amifloxacin, amifostine, 	 dopyrine Hydrochloride, benzisoxazole, Benzocaine, ben- 
Amilcacin, Amiloride Hydrochloride, Aminacrine Hydro- 	 zochlorins, Benzoctamine Hydrochloride, Benzodepa, ben- 
chloride, Aminobenzoate Potassium, Aminobenzoate 	 zoidazoxan, 	 Benzonatate, 	 Benzoyl 	 Peroxide, 
Sodium, Aminocaproic Acid, Aminoglutethimide, Amino-  45 benzoylstaurosporine, Benzquinamide, Benzthiazide, benz- 
hippurate Sodium, aminolevulinic acid, Aminophylline, A 	 tropine, Benztropine Mesylate, Benzydamine Hydrochlo- 
minorex, Aminosalicylate sodium, Aminosalicylic acid, 	 ride, Benzylpenicilloyl Polylysine, bepridil, Bepridil Hydro- 
Amiodarone, Amiprilose Hydrochloride, Amiquinsin Hydro- 	 chloride, Beractant, Beraprost, Berefrine, berlafenone, 
chloride, amisulpride, Amitraz, Amitriptyline Hydrochlo- 	 bertosamil, Berythromycin, besipirdine, betaalethine, 
ride, Amlexanox, amlodipine, amlodipine besylate, Amobar-  5o betaclamycin B, Betamethasone, betamipron, betaxolol, 
bital Sodium, Amodiaquine, Amodiaquine Hydrochloride, 	 Betaxolol Hydrochloride, Bethanechol Chloride, Bethani- 
Amorolfine, Amoxapine, Amoxicillin, Amphecloral, 	 dine Sulfate, betulinic acid, bevacizumab, bevantolol, Bevan- 
Amphetamine, Amphetamine Sulfate, Amphomycin, 	 tolol Hydrochloride, Bezafibrate, Bialamicol Hydrochloride, 
Amphoterin B, Ampicillin, ampiroxieam, Ampyzine Sulfate, 	 Biapenem, Bicalutamide, Bicifadine Hydrochloride, Biclodil 
Amquinate, Amrinone, amrubicin, Amsacrine, Amylase, 55 Hydrochloride, Bidisomide, bifemelane, Bifonazole, 
amylin, amythiamicin, Anagestone Acetate, anagrelide, 	 bimakalim, Bimatoprost, bimithil, Bindarit, Biniramycin, 
Anakinra, ananain, anaritide, Anaritide Acetate, Anastrozole, 	 binospirone, bioxalomycin, Bipenamol Hydrochloride, 
Anazolene Sodium, Ancrod, andrographolide, Androstenedi- 	 Biperiden, Biphenamine Hydrochloride, biriperone, bisant- 
one, Angiotensin Amide, Anidoxime, Anileridine, Anilopam 	 rene, bisaramil, bisaziridinylspermine, bis-benzimidzole A, 
Hydrochloride, Aniracetam, Anirolac, Anisotropine Methyl- 6o bis-benzimidazole B, bisnafide, Bisobrin Lactate, Bisoprolol, 
bromide, Anistreplase, Anitrazafen, anordrin, antagonist D, 	 Bisoprolol fumarate, Bispyrithione Magsulfex, bistramide D, 
antagonist G, antarelix, Antazoline Phosphate, Anthelmycin, 	 bistramide K, bistratene A, Bithionolate Sodium, Bitolterol 
Anthralin, Anthramyciantiandrogen, antiestrogen, antine- 	 Mesylate, Bivalirudin, Bizelesin, Bleomycin Sulfate, bol- 
oplaston, Antipyrine, antisense oligonucleotides, apadoline, 	 dine, Bolandiol Dipropionate, Bolasterone, Boldenone 
apafant, Apalcillin Sodium, apaxifylline, Apazone, aphidi-  65 Undecylenate, Bolenol, Bolmantalate, bopindolol, Bosentan, 
colin glycinate, Apixifylline, Apomorphine Hydrochloride, 	 Botulin toxin, Boxidine, brefeldin, breflate, Brequinar 
apraclonidine, Apraclonidine Hydrochloride, Apramycin, 	 Sodium, Bretazenil, Bretylium Tosylate, Brifentanil Hydro- 
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chloride, brimonidine, Brinolase, Brocresine, Brocrinat, Bro-
foxine, Bromadoline Maleate, Bromazepam, Bromchlo-
renone, Bromelain, bromfenac, Brominidione, 
Bromocriptine, Bromodiphenhydramine Hydrochloride, 
Bromoxanide, Bromperidol, Bromperidol Decanoate, Bro-
mpheniramine Maleate, Broperamole, Bropirimine, Broti-
zolam, Bucamide Maleate, bucindolol, Buclizine Hydrochlo-
ride, Bucromar one, Budesonide, budipine, budotitane, 
Buformin, Bumetanide, Bunaprolast, bunazosin, Bunolol 
Hydrochloride, Bupicomide, Bupivacaine Hydrochloride, 
Buprenorphine, Buprenorphine Hydrochloride, Bupropion, 
bupropion hydrobromide, Bupropion Hydrochloride, Bura-
mate, Buserelin Acetate, Buspirone Hydrochloride, Busul-
fan, Butabarbital, Butacetin, Butaclamol Hydrochloride, 
Butalbital, Butamben, Butamirate Citrate, Butaperazine, 
Butaprost, Butedronate Tetrasodium, butenafine, Buterizine, 
buthioninc sulfoximine, Butikacin, Butilfenin, Butirosin Sul-
fate, Butixirate, butixocortpropionate, Butoconazole Nitrate, 
Butonate, Butopamine, Butoprozine Hydrochloride, Butor-
phanol, Butoxamine Hydrochloride, Butriptyline Hydrochlo-
ride, Cabergoline, Cactinomycin, Cadexomer Iodine, Caf-
feine, calanolide A, Calcifediol, Calcipotriene, calcipotriol, 
Calcitonin, Calcitriol, Calcium Undecylenate, calphostin C, 
Calusterone, Cambendazole, Cammonam Sodium, camon-
agrel, canary pox IL-2, candesartan, candesartan cilexetil, 
Candicidin, candoxatril, candoxatrilat, Canighbose, Can-
renoate Potassium, Canrenone, capecitabine, Capobenate 
Sodium, Capobenic Acid, Capreomycin Sulfate, capromab, 
capsaicin, Captopril, Capuride, Car bocysteine, Caracemide, 
Carbachol, Carbadox, Carbamazepine, Carbamide Peroxide, 
Carbantel Lauryl Sulfate, Carbaspirin Calcium, Carbazeran, 
carbazomycin C, Carbenicillin Potassium, Carbenoxolone 
Sodium, Carbetimer, carbetocin, Carbidopa, Carbidopa-
Levodopa, Carbinoxamine Maleate, Carbiphene Hydrochlo-
ride, Carbocloral, Carbol-Fuchsin, Carboplatin, Carboprost, 
carbovir, carboxamide-amino-triazo-le, carboxyamidotriaz-
ole, carboxymethylated beta-1,3-glucan, Carbuterol Hydro-
chloride, CaRest M3, Carfentanil Citrate, Carisoprodol, Car-
mantadine, Carmustine, CARN 700, Carnidazole, 
Caroxazone, carperitide, Carphenazine Maleate, Carprofen, 
Carsatrin Succinate, Cartazolate, carteolol, Carteolol Hydro-
chloride, Carubicin Hydrochloride, carvedilol, carvotroline, 
Carvotroline Hydrochloride, carzelesin, Caspofungin, 
castanospermine, caurumonam, cebaracetam, cecropin B, 
Cedefingol, Cefaclor, Cefadroxil, Cefamandole, Cefaparole, 
Cefatrizine, Cefazaflur Sodium, Cefazolin, cefcapene piv-
oxil, cefdaloxime pentexil tosilate, Cefdinir, cefditoren piv-
oxil, Cefepime, cefetamet, Cefetecol, cefixime, cefluprenam, 
Cefinenoxime Hydrochloride, Cefinetazole, cefminlox, cefo-
dizime, Cefonicid Sodium, Cefoperazone, Cefoperazone 
Sodium, Ceforanide, cefoselis, Cefotaxime Sodium, 
Cefotetan, cefotiam, Cefoxitin, cefozopran, cefpimizole, 
Cefpiramide, cefpirome, cefpodoxime proxetil, cefprozil, 
Cefroxadine, cefsulodin, Ceftazidime, cefteram, ceftibuten, 
Ceftizoxime Sodium, ceftriaxooe, Cefuroxime, celastrol, 
Celecoxib, celikalim, celiprolol, cepacidiineA, Cephacetrile 
Sodium, Cephalexin, Cephaloglycin, Cephaloridine, Cepha-
lothin Sodium, Cephapirin Sodium, Cephradine, cer-
iclamine, cerivastatin, Ceruletide, Ceronapril, Certolizumab 
Pegol, certoparin sodium, Cetaben Sodium, Cetalkonium 
Chloride, Cetamolol Hydrochloride, Cethuperazone, 
cetiedil, cetirizine, Cetophenicol, Cetraxate Hydrochloride, 
Cetrizine hydrochloride, cetrorelix, Cetuximab, Cetylpyri-
dinium Chloride, Chenodiol, Chlophedianol Hydrochloride, 
Chloral Betaine, Chlorambucil, Chloramphenicol, Chlordan-
toin, Chlordiazepoxide, Chlorhexidine Gluconate, chlorins, 
Chlormadinone Acetate, chloroorienticin A, Chloroprocaine 
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Hydrochloride, Chloropropamide, Chloroquine, chloroqui-
noxaline sulfonamide, Chlorothiazide, Chlorotrianisene, 
Chloroxine, Chloroxylenol, Chlorpheniramine Maleate, 
Chlorphenesin Carbamate, Chlorpheniramine maleate, Chlo- 
5 rpromazine, Chlorpromazine hydrochloride, Chlorpropam-
ide, Chlorprothixene, Chlortetracycline Bisulfate, Chlortha-
lidone, Chlorzoxazone, Cholestyramine Resin, Chromonar 
Hydrochloride, cibenzoline, cicaprost, Ciclafrine Hydro-
chloride, Ciclazindol, ciclesonide, cicletanine, Ciclopirox, 
io Cicloprofen, cicloprolol, Cidofovir, Cidoxepin Hydrochlo-
ride, Cifenline, Ciglitazone, Ciladopa Hydrochloride, 
cilansetron, Cilastatin, Cilastatin Sodium, Cilazapril, cilnid-
ipine, Cilobamine Mesylate, cilobradine, Cilofungin, cilosta-
zol, Cimaterol, Cimetidine, cimetropium bromide, Cinacal- 
15 cet, Cinalukast, Cinanserin Hydrochloride, Cinepazet 
Maleate, Cinflumide, Cingestol, cinitapride, Cinnamedrine, 
Cinnarizine, cinolazepam, Cinoxacin, Cinperene, Cinro-
mide, Cintazone, Cintriamide, Cioteronel, Cipamfylline, 
Ciprefadol Succinate, Ciprocinonide, Ciprofibrate, Ciprof- 
20 loxacin, ciprostene, Ciramadol, Cirolemycin, Cisplatin, 
cisapride, cisatracuriumbesilate, Cisconazole, cis-porphyrin, 
cistinexine, citalopram, citalopram hydrobromide, Citena-
mide, citicoline, citreamicin alpha, cladribine, Clamoxyquin 
Hydrochloride, Clarithromycin, clausenamide, Clavulanate 
25 Potassium, Clazolam, Clazolimine, clebopride, Clemastine, 
Clentiazem Maleate, Clidinium Bromide, clinafloxacin, 
Clindamycin, clindamycin hydrochloride, Clioquinol, Cliox-
anide, Cliprofen, clobazam, Clobetasol Propionate, Clobeta-
sone Butyrate, Clocortolone Acetate, Clodanolene, Clodazon 
3o Hydrochloride, clodronic acid, Clofazimine, Clofibrate, Clo-
filium Phosphate, Cloge stone Acetate, Clomacran Phos-
phate, Clomegestone Acetate, Clometherone, clomethiazole, 
clomifeneanalogues, Clominorex, Clomiphene, Clomi-
pramine Hydrochloride, Clonazepam, Clonidine, Clonidine 
35 hydrochloride, Clofibrate, Clonixeril, Clonixin, Clopamide, 
Clopenthixol, Cloperidone Hydrochloride, clopidogrel, Clo-
pidogrel bisulfate, Clopimozide, Clopipazan Mesylate, Clo-
pirac, Cloprednol, Cloprostenol Sodium, Clorazepate Dipo-
tassium, Clorethate, Clorexolone, Cloroperone 
4o Hydrochloride, Clorprenaline Hydrochloride, Clorsulon, 
Clortemine Hydrochloride, Closantel, Closiramine Acetu-
rate, Clothiapine, Clothixamide Maleate Cloticasone Propi-
onate, Clotrimazole, Cloxacillin Benzathine, Cloxacillin 
Sodium, Cloxyquin, Clozapine, Co-Amoxiclav, Cocaine, 
45 Coccidioidin, Codeine, Codeine phosphate, Codoxime, 
Colchicine, Colesevelam, colestimide, Colestipol Hydro-
chloride, Colestolone, Colforsin, Colfosceril Palmitate, 
Colistimethate Sodium, Colistin Sulfate, collismycin A, col-
lismycin B, Colterol Mesylate, combretastatin A4, com- 
50 plestatin, conagenin, Conorphone Hydrochloride, contignas-
terol, contortrostatin, Cormethasone Acetate, Corticorelin 
Ovine Tnflutate, Corticotropin, Cortisone Acetate, Cortiva-
zol, Cortodoxone, cosalane, costatolide, Cosyntropin, coti-
nine, Coumadin, Coumermycin, crambescidin, Crilvastatin, 
55 crisnatol, Cromitrile Sodium, Cromolyn Sodium, Crotami-
ton, cryptophycin, cucumariosid, Cuprimyxin, curacin A, 
curdlan sulfate, curiosin, Cyclacillin, Cyclazocine, cycla-
zosin, Cyclindole, Cycliramine Maleate, Cyclizine, 
Cyclobendazole, cyclobenzaprine, cyclobenzaprine hydro- 
60 chloride, cyclobut A, cyclobut G, cyclocapron, Cycloguanil 
Pamoate, Cycloheximide, cyclopentanthraquinones, Cyclo-
penthiazide, Cyclopentolate Hydrochloride, Cyclophenazine 
Hydrochloride, Cyclophosphamide, cycloplatam, Cyclopro-
pane, Cycloserine, cyclosin, Cyclosporine, cyclothialidine, 
65 Cyclothiazide, cyclothiazomycin, Cyheptamide, cypemycin, 
Cyponamine Hydrochloride, Cyprazepam, Cyproheptadine 
Hydrochloride, Cyprolidol Hydrochloride, cyproterone, 
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Cyproximide, Cysteamine, Cysteine Hydrochloride, Cystine, 	 mesylate, doxycydine, Drospirenone, Duloxetine, Dutast- 
Cytarabine, Cytarabine Hydrochloride, cytarabine ocfosfate, 	 eride, Ebastine, ebiratide, ebrotidine, ebselen, ecabapide, 
cytochalasin B, cytostatin, Dacarbazine, dacliximab, dac- 	 ecabet, ecadotril, ecdisteron, echicetin, echistatin, 
timicin, Dactinomycin, daidzein, Daledalin Tosylate, dalfo- 	 Echothiophate Iodide, Eclanamine Maleate, Eclazolast, eco- 
pristin, Dalteparin Sodium, Daltroban, Dalvastatin, danap-  5 mustine, Econazole, ecteinascidin 722, eculizumab, edara- 
aroid, Danazol, Dantrolene, daphlnodorin A, dapiprazole, 	 vone, Edatrexate, edelfosine, Edifolone Acetate, edobaco- 
dapitant, Dapoxetine Hydrochloride, Dapsone, Daptomycin, 	 mab, Edoxudine, edrecolomab, Edrophonium Chloride, 
darbepoetin alfa, Darglitazone Sodium, darifenacin, darlucin 	 edroxyprogesteone Acetate, Efavirenz, efegatran, eflorni- 
A, Darodipine, darsidomine, Daunorubicin Hydrochloride, 	 thine, efonidipine, egualcen, Elantrine, eleatonin, elemene, 
Dazadrol Maleate, Dazepinil Hydrochloride, Dazmegrel, io eletriptan, elgodipine, eliprodil, Elsamitrucin, eltenae, 
Dazopride Fumarate, Dazoxiben Hydrochloride, DCRM 197 
	
Elucaine, emailcalim, emedastine, Emetine Hydrochloride, 
protein, Debrisoquin Sulfate, Decitabine, deferiprone, 	 emiglitate, Emilium Tosylate, emitefur, emoctakin, Emtricit- 
deflazacort, Dehydrocholic Acid, dehydrodidemninB, Dehy- 	 abine, Enadoline Hydrochloride, Enailciren, enalapril, enala- 
droepiandrosterone, delapril, Delapril Hydrochloride, 	 pril maleate, enazadrem, Encyprate, Endralazine Mesylate, 
Delavirdine Mesylate, delequamine, delfaprazine, Delmadi-  15 Endrysone, Enflurane, englitazone, Enilconazole, Eniso- 
none Acetate, delmopinol, delphinidin, Demecarium Bro- 	 prost, Enlimomab, Enloplatin, Enofelast, Enolicam Sodium, 
mide, Demeclocycline, Demecycline, Demoxepam, Deno- 	 Enoxacin, enoxacin, enoxaparin sodium, Enoxaparin 
fungin, deoxypyridinoline, Depakote, deprodone, Deprostil, 	 Sodium, Enoximone, Enpiroline Phosphate, Enprofylline, 
depsidomycin, deramciclane, dermatan sulfate, Desciclovir, 	 Enpromate, 	 entacapone, 	 enterostatin, 	 Enviradene, 
DescinoloneAcetonide, Desfurane, Desipramine Hydrochlo-  20 Enviroxime, Ephedrine, Epicillin, Epimestrol, Epinephrine, 
ride, desirudin, Deslanoside, Desloratadine, deslorelin, des- 	 Epinephryl Borate, Epipropidine, Epirizole, epirubicin, 
mopressin, Desmopressin sulfate, desogestrel, Desonide, 	 Epitetracycline Hydrochloride, Epithiazide, Epoetin Alfa, 
Desoximetasone, desoxoamiodarone, Desoxy-corticoster- 	 Epoetin Beta, Epoprostenol, Epoprostenol Sodium, 
one Acetate, detajmiumbitartrate, Deterenol Hydrochloride, 	 epoxymexrenone, epristeride, Eprosartan, eptastigmine, 
Detirelix Acetate, Devazepide, Dexamethasone, Dexamisole, 25 equilenin, Equilin, Erbulozole, erdosteine, Ergoloid Mesy- 
Dexbrompheniramine Maleate, Dexchlorpheniramine Male- 	 lates, Ergonovine Maleate, Ergotamine Tartrate, Erlotinib, 
ate, Dexclamol Hydrochloride, Dexetimide, Dexfenflu- 	 ersentilide, Ersofermin, erythritol, Erythrityl Tetranitrate, 
ramine Hydrochloride, dexifosfamide, Deximafen, dexketo- 	 Erythromycin, Erythropoetin, Escitalopram, Esmolol Hydro- 
profen, dexloxiglumide, Dexmedetomidine, Dexormaplatin, 	 chloride, esomeprazole, Esorubicin Hydrochloride, Espro- 
Dexoxadrol Hydrochloride, Dexpanthenol, Dexpemedolac, so quip Hydrochloride, Estazolam, Estradiol, Estramustine, 
Dexpropranolol Hydrochloride, Dexrazoxane, dexsotalol, 	 Estrazinol Hydrobromide, Estriol, Estrofurate, Estrogen, 
dextrin 2-sulphate, Dextroamphetamine, Dextromethorphan, 	 Estrone, Estropipate, esuprone, Eszopiclone, Etafedrine 
Dextrorphan Hydrochloride, Dextrothyroxine Sodium, dex- 	 Hydrochloride, etanercept, Etanidazole, etanterol, Etarotene, 
verapamil, Dezaguanine, dezinamide, dezocine, Diacetolol 
	
Etazolate Hydrochloride, Eterobarb, ethacizin, Ethacrynate 
Hydrochloride, Diamocaine Cyclamate, Diapamide, Diatri-  35 Sodium, Ethacrynic Acid, Ethambutol Hydrochloride, 
zoate Meglumine, Diatrizoic Acid, Diaveridine, Diazepam, 	 Ethamivan, Ethanolamine Oleate, Ethehlorvynol, Ethembu- 
Diaziquone, Diazoxide, Dibenzepin Hydrochloride, Diben- 	 tol hydrochloride, Ethinyl estradiol, Ethiodized Oil, Ethiona- 
zothiophene, Dibucaine, Dichliorvos, Dichloralphenazone, 	 mide, Ethonam Nitrate, Ethopropazine Hydrochloride, Etho- 
Dichlorphenamide, Dicirenone, Diclofenac, Diclofenac 	 suximide, 	 Ethosuximide, 	 Ethotoin, 	 Ethoxazene 
Sodium, Dicloxacillin, dicranin, Dicumarol, Dicyclomine 4o Hydrochloride, Ethybenztropine, Ethyl Chloride, Ethyl 
Hydrochloride, Didanosine, didemnin B, didox, Dienestrol, 	 Dibunate, Ethylestrenol, Ethyndiol, Ethynerone, ethynl estra- 
dienogest, Diethylcarbamazine Citrate, diethylhomosper- 	 diol, Ethyndiol Diacetate, Etibendazole, Etidocaine, Etidr- 
mine, diethylnorspermine, Diethylpropion Hydrochloride, 	 onate Disodium, Etidronic Acid, Etifenin, Etintidine Hydro- 
Diethylstilbestrol, Difenoximide Hydrochloride, Difenoxin, 	 chloride, etizolam, Etodolac, Etofenamate, Etoformin 
Diflorasone Diacetate, Difloxacin Hydrochloride, Difluanine 45 Hydrochloride, Etomidate, Etonogestrel, Etoperidone 
Hydrochloride, Diflucortolone, Diflumidone Sodium, 	 Hydrochloride, Etoposide, Etoprine, etoricoxib, Etoxadrol 
Diflunisal, Difluprednate, Diftalone, Digitalis, Digitoxin, 	 Hydrochloride, Etozolin, etrabamine, etravirine, Etretinate, 
Digoxin, Dihexyverine Hydrochloride, dihydrexidine, dihy- 	 Etryptamine Acetate, Eucatropine Hydrochloride, Eugenol, 
dro-5-azacytidine, Dihydrocodeine Bitartrate, Dihydroer- 	 Euprocin Hydrochloride, eveminomicin, Exametazime, 
gotamine Mesylate, Dihydroestosterone, Dihydrostreptomy-  50 examorelin, Exaprolol Hydrochloride, exemestane, 
cin Sulfate, Dihydrotachysterol, Dilantin, Dilevalol 
	
Exenatide, Ezetimibe, Ezetimibe, Factor VII, fadrozole, fae- 
Hydrochloride, Diltiazem Hydrochloride, Dimefadane, 	 riefungin, Famciclovir, Famotidine, Fampridine, fantofarone, 
Dimefline Hydrochloride, Dimenhydrinate, Dimercaprol, 	 Fantridone Hydrochloride, faropenem, fasidotril, fasudil, 
Dimethadione, Dimethindene Maleate, Dimethisterone, 	 fazarabine, fedotozine, Felbamate, felbamate, Felbinac, 
Dimethyl Sulfoxide, dimethylhomospermine, dimethylpros-  55 Felodipine, Felypressin, Fenalamide, Fenamole, Fenbenda- 
taglandin Al, dimiracetam, Dimoxamine Hydrochloride, 	 zole, Fenbufen, Fencibutirol, Fenclofenac, Fenclonine, Fen- 
Dinoprost, Dinoprostone, Dioxadrol Hydrochloride, dioxa- 	 clorac, Fendosal, Fenestrel, Fenethylline Hydrochloride, 
mycin, diphenhydramine, Diphenhydramine Citrate, 	 Fenfluramine Hydrochloride, Fengabine, Fenimide, Fen- 
Diphenidol, Diphenoxylate Hydrochloride, diphenylspiro- 	 isorex, Fenmetozole Hydrochloride, Fenmetramide, 
mustine, Dipivefin Hydrochloride, Dipivefrin, diplien-  6o Fenobam, Fenoctimine Sulfate, Fenofibrate, fenoldopam, 
cyprone, diprafenone, dipropylnorspermine, Dipyridamole, 	 Fenoprofen, Fenoterol, Fenpipalone, Fenprinast Hydrochlo- 
Dipyrithione, Dipyrone, dirithromycin, discodermolide, Dis- 	 ride, Fenprostalene, Fenquizone, fenretinide, fenspiride, fen- 
obutamide, Disofenin, Disopyramide, Disoxaril, disulfuram, 	 tanyl, Fentanyl Citrate, Fentiazac, Fenticlor, fenticonazole, 
Ditekiren, Divalproex Sodium, Dizocilpine Maleate, DL-me- 	 Fenyripol Hydrochloride, fepradinol, ferpifosate sodium, fer- 
thionine, Dobutamine, docarpamine, Docebenone, Doc-  65 ristene, ferrixan, Ferrous Sulfate, Ferumoxides, ferumoxsil, 
etaxel, Doconazole, docosanol, dofetilide, dolasetron, Done- 	 Fetoxylate Hydrochloride, Fexofenadine, fexofenadine 
pezil, doripenem, Dorzolamide, Doxazosin, doxazosin 	 hydrochloride, Fezolamine Fumarate, Fiacitabine, Fialuri- 
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dine, fibmoxef, Fibrinogen, Filgrastim, Filipin, Finasteride, 	 mide, hexamethylenebisacetamide, Hexedine, Hexobendine, 
fiorfenicol, fiorifenine, fiosatidil, fiumecinol, fiunarizine, 	 Hexoprenaline Sulfate, Hexylresorcinol, Histamine Phos- 
fiuparoxan, fiupirtine, fiurithromycin, fiutrimazole, fiuvasta- 	 phate, Histidine, Histoplasmin, Histrelin, histrelin acetate, 
tin, fiuvoxamine, Flavodilol Maleate, flavopiridol, Flavoxate 	 Homatropine Hydrobromide, Hoquizil Hydrochloride, 
Hydrochloride, Flazalone, flecamide, flerobuterol, Fleroxa-  5 Human chorionic gonadotropin, Human growth hormone, 
cin, flesinoxan, Flestolol Sulfate, Fletazepam, flezelastine, 	 Hycanthone, Hydralazine Hydrochloride, Hydralazine Polis- 
flobufen, Floctafenine, Flordipine, Flosequinan, Floxacillin, 	 tirex, Hydrochlorothiazide, Hydrocodone Bitartrate, Hydro- 
Floxuridine, fluasterone, Fluazacort, Flubanilate Hydrochlo- 	 cortisone, Hydroflumethiazide, Hydromorphone Hydrochlo- 
ride, Flubendazole, Flucindole, Flucloronide, Fluconazole, 	 ride, 	 Hydroxyamphetamine 	 Hydrobromide, 
Flucytosine, Fludalanine, Fludarabine Phosphate, Fludazo-  io Hydroxychloroquine Sulfate, Hydroxyphenamate, Hydrox- 
nium Chloride, Fludeoxyglucose, Fludorex, Fludrocortisone 	 yprogesterone Caproate, Hydroxyurea, Hydroxyzine Hydro- 
Acetate, Flufenamic Acid, Flufenisal, Flumazenil, Flume- 	 chloride, Hymecromone, Hyoscyamine, hypericin, Ibafloxa- 
quine, Flumeridone, Flumethasone, Flumetramide, Flumeza- 	 cin, Ibandronate, ibogaine, Ibopam, ibudilast, Ibufenac, 
pine, Fluminorex, Flumizole, Flumoxonide, Flunidazole, 	 Ibuprofen, Ibutilide Fumarate, Icatibant Acetate, Ichtham- 
Flunisolide, Flunitrazepam, Flunixin, fluocalcitriol, Fluoci-  15 mol, Icotidine, idarubicin, idoxifene, Idoxuridine, idraman- 
nolone Acetonide, Fluocinonide, Fluocortin Butyl, Fluocor- 	 tone, Ifetroban, Ifosfamide, Ilepeimide, illimaquinone, ilmo- 
tolone, Fluorescein, fluorodaunorunicin hydrochloride, Fluo- 	 fosin, ilomastat, Ilonidap, iloperidone, iloprost, Imafen 
rodopa, 	 Fluorometholone, Fluorouracil, 	 Fluotracen 	 Hydrochloride, Imatinib, Imazodan Hydrochloride, imi- 
Hydrochloride, Fluoxetine, Fluoxetine hydrochloride, Flu- 	 dapril, imidazenil, imidazoacridone, Imidecyl Iodine, Imi- 
oxymesterone, Fluperamide, Fluperolone Acetate, Fluphena-  2o docarb Hydrochloride, Imidoline Hydrochloride, Imidurea, 
zine Decanoate, Fluprednisolone, Fluproquazone, Flupros- 	 Imiglucerase, Imiloxan Hydrochloride, Imipenem, Imi- 
tenol Sodium, Fluquazone, Fluradoline Hydrochloride, 	 pramine Hydrochloride, imiquimod, Impromidine Hydro- 
Flurandrenolide, Flurazepam Hydrochloride, Flurbiprofen, 	 chloride, Indacrinone, Indapamide, Indecamide Hydrochlo- 
Fluretofen, Fluorocitabine, Fluorofamide, Fluorogestone 	 ride, Indeloxazine Hydrochloride, Indigotindisulfonate 
Acetate, Fluorothyl, Fluoroxene, Fluspiperone, Fluspirilene, 25 Sodium, indinavir, Indinavir sulfate, Indocyanine Green, 
Fluticasone, Fluticasone Propionate, Flutroline, Fluvastatin, 	 Indolapril 	 Hydrochloride, 	 Indolidan, 	 indometacin, 
Fluvastatin Sodium, Fluzinamide, Folic Acid, Follicle regu- 	 Indomethacin Sodium, Indoprofen, indoramin, Indorenate 
latory protein, Folliculostatin, Follitropin alfa, Follitropin 	 Hydrochloride, Indoxole, Indriline Hydrochloride, inflix- 
beta, Fomepizole, Fonazine Mesylate, forasartan, forfen- 	 imab, inocoterone, inogatran, inolimomab, Inositol Niaci- 
imex, forfenirmex, formestane, Formocortal, formoterol, so pate, Insulin, Interferon beta-la, Intrazole, Intriptyline 
Fosarilate, Fosazepam, Foscamet Sodium, fosfomycin, Fos- 	 Hydrochloride, iobenguane, Iobenzamic Acid, iobitridol, 
fonet Sodium, fosinopril, Fosinopril sodium, Fosinoprilat, 	 Iodine, iodoamiloride, iododoxorubicin, iofratol, iomeprol, 
fosphenyloin, Fosquidone, Fostedil, fostriecin, fotemustine, 	 iopentol, iopromide, iopyrol, iotriside, ioxilan, ipazilide, 
Fuchsin, Fumoxicillin, Fungimycin, Furaprofen, Furazoli- 	 ipenoxazone, ipidacrine, Ipodate Calcium, ipomeanol, Ipra- 
done, Furazolium Chloride, Furegrelate Sodium, Furobufen, 35 tropium, Ipratropium Bromide, ipriflavone, Iprindole, Ipro- 
Furodazole, Furosemide, Fusidate Sodium, Fusidic Acid, 	 fenin, Ipronidazole, Iproplatin, Iproxamine Hydrochloride, 
Gabapentin, Gadobenate Dimeglumine, gadobenic acid, 	 ipsapirone, irbesartan, irinotecan, irloxacin, iroplact, irsogla- 
gadobutrol, Gadodiamide, gadolinium texaphyrin, Gadopen- 	 din, Irtemazole, isalsteine, Isamoxole, isbogrel, Isepamicin, 
tetate Dimegiumine, gadoteric acid, Gadoteridol, Gadover- 	 isobengazole, Isobutamben, Isocarboxazid, Isoconazole, Iso- 
setamide, galantamine, galdansetron, Galdansetron Hydro-  40 etharine, isofloxythepin, Isoflupredone Acetate, Isoflurane, 
chloride, Gallamine Triethiodide, gallium nitrate, gallopamil, 	 Isofluorophate, isohomohalicondrin B, Isoleucine, Isoma- 
galocitabine, Gamfexine, gamolenic acid, Ganciclovir, 	 zole Hydrochloride, Isomylamine Hydrochloride, Isoniazid, 
ganirelix, Gemcadiol, Gemcitabine, Gemeprost, Gemfi- 	 Isopropamide Iodide, Isopropyl Alcohol, isopropyl unopros- 
brozil, Gentamicin Sulfate, Gentian Violet, gepirone, Gesta- 	 tone, Isoproterenol Hydrochloride, Isosorbide, Isosorbide 
clone, Gestodene, Gestonorone Caproate, Gestrinone, Gev-  45 Mononitrate, Isotiquimide, Isotretinoin, Isoxepac, Isoxicam, 
otroline Hydrochloride, girisopam, glargine insulin, 	 Isoxsuprine Hydrochloride, isradipine, itameline, itasetron, 
glaspimod, Glatiramer, glaucocalyxinA, Glemanserin, Glia- 	 Itazigrel, itopride, Itraconazole, Ivermectin, ixabepilone, jas- 
milide, Glibomuride, Glicetanile Sodium, Glifiumide, 	 plakinolide, Jemefloxacin, Jesopitron, Josamycin, kahalalide 
Glimepiride, Glipizide, Gloximonam, Glucagon, glutapy- 	 F, Kalafungin, Kanamycin Sulfate, ketamine, Ketanserin, 
rone, Glutethimide, Glyburide, glycopine, glycopril, Glyco-  5o Ketazocine, Ketazolam, Kethoxal, Ketipramine Fumarate, 
pyrrolate, Glyhexamide, Glymidine Sodium, Glyoctamide, 	 Ketoconazole, Ketoprofen, Ketorfanol, ketorolac, Ketotifen 
Glyparamide, Gold Au-198, Gonadoctrinins, Gonadorelin, 	 Fumarate, Kitasamycin, Labetalol Hydrochloride, Lacid- 
Gonadotropins, Goserelin, Gramicidin, Granisetron, grepa- 	 ipine, lacidipine, lactitol, lactivicin, Lactobionate, laennec, 
floxacin, Griseofulvin, Guaiapate, Guaithylline, Guanabenz, 	 lafutidine, 1-alphahydroxyvitamin D2, lamellarin-N triac- 
Guanabenz Acetate, Guanadrel Sulfate, Guancydine, 55 etate, lamifiban, Lamivudine, Lamotrigine, lanoconazole, 
Guanethidine Monosulfate, Guanfacine Hydrochloride, 	 Lanoxin, lanperisone, lanreotide, lanreotide acetate, Lanso- 
Guanisoquin Sulfate, Guanoclor Sulfate, Guanoctine Hydro- 	 prazole,lapatinib,laropiprant,latanoprost,lateritin,lauroca- 
chloride, Guanoxabenz, Guanoxan Sulfate, Guanoxyfen Sul- 	 pram, Lauryl Isoquinolinium Bromide, Lavoltidine Succi- 
fate, Gusperimus Trihydrochloride, Halazepam, Halcinon- 	 nate, lazabemide, Lecimibide, leinamycin, lemildipine, 
ide, halichondrin B, Halobetasol Propionate, halofantrine, 60 leminoprazole, lenercept, Leniquinsin, lenograstim, Lenper- 
Halofantrine Hydrochloride, Halofenate, Halofuginone 	 one, lentinan sulfate, leptin, leptolstatin, lercanidipine, Ler- 
Hydrobromide, halomon, Halopemide, Haloperidol, halopre- 	 gotrile, lerisetron, Letimide Hydrochloride, letrazuril, letro- 
done, Haloprogesterone, Haloprogin, Halothane, Halquinols, 	 zole, Leucine, leucomyzin, leuprolide, Leuprolide Acetate, 
Hamycin, hatomamicin, hatomarubigin A, hatomarubigin B, 	 leuprorelin, Levalbuterol, Levamfetamine Succinate, levami- 
hatomarubigin C, hatomarubigin D, Heparin Sodium, hep-  65 sole, Levdobutamine Lactobionate, Leveromakalim, leveti- 
sulfam, heregulin, Hetacillin, Heterooium Bromide, 	 racetam, Leveycloserine, levobetaxolol, levobunolol, 
Hexachlorophene Hydrogen Peroxide, Hexafluorenium Bro- 	 levobupivacaine, levocabastine, levocarnitine, levocetirizine, 
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levocetirizine dhydrochloride, Levodopa, levodropropizine, 	 Sodium, merbarone, Mercaptopurine, Mercufenol Chloride, 
levofloxacin, Levofuraltadone, Levoleucovorin Calcium, 	 Merisoprol, Meropenem, Mesalamine, Meseclazone, 
Levomethadyl Acetate, Levomethadyl Acetate Hydrochlo- 	 Mesoridazine, Mesterolone, Mestranol, Mesuprine Hydro- 
ride, levomoprolol, Levonantradol Hydrochloride, Levonor- 	 chloride, Metalol Hydrochloride, Metaproterenol Polistirex, 
defrin, Levonorgestrel, Levopropoxyphene Napsylate, Levo-  5 Metaraminol Bitartrate, Metaxalone, Meteneprost, meter- 
propylcillin Potassium, levormeloxifene, Levorphanol 	 elin, Metformin, Methacholine Chloride, Methacycline, 
Tartrate, levosimendan, levosulpiride, Levothyroxine, 	 methadone, Methadyl Acetate, Methalthiazide, Methamphet- 
Levothyroxine Sodium, Levoxadrol Hydrochloride, Lexi- 	 amine Hydrochloride, Methaqualone, Methazolamide, 
pafant, Lexithromycin, liarozole, Libenzapril, Lidamidine 	 Methdilazine, Methenamine, Methenolone Acetate, Meth- 
Hydrochloride, Lidocaine, Lidofenin, Lidoflazine, Lifarizin, io etoin, Methicillin Sodium, Methimazole, methioninase, 
Lifibrate, Lifibrol, Linarotene, Lincomycin, Linezolid, 	 Methionine, Methisazone, Methixene Hydrochloride, 
Linogliride, Linopirdine, linotroban, linsidomine, lintitript, 	 Methocarbamol, Methohexital Sodium, Methopholine, 
lintopride, Liothyronine I-125, liothyronine sodium, Liotrix, 	 Methotrexate, Methotrimeprazine, methoxatone, methoxy 
lirexapride, Lisdexamfetamine Dimesylate, lisinopril, Lispro 	 polyethylene glycol-epoetinbeta, Methoxyflurane, Methsux- 
insulin, lissoclinamide, Lixazinone Sulfate, lobaplatin, 15 imide, Methyclothiazide, Methyl Palmoxirate, Methylatro- 
Lobenzarit Sodium, Lobucavir, locarmate Meglumine, locar- 	 pine Nitrate, Methylbenzethonium Chloride, Methyldopa, 
mic Acid, locetamic Acid, lodamide, Lodelaben, lodipamide 	 Methyldopate Hydrochloride, Methylene Blue, Methyler- 
Meglumine, lodixanol, IodoantipyrineI-131, Iodocholesterol 	 gonovine Maleate, methylhistamine, methylinosine mono- 
I-131, Iodohippurate Sodium I-131, Iodopyracet I-125, 	 phosphate, Methylphenidate, Methylprednisolone, Methylt- 
Iodoquinol, Iodoxamate Meglumine, lodoxamide, Iodox-  20 estosterone, Methynodiol Diacelate, Methysergide, 
amie Acid, Lofemizole Hydrochloride, Lofentanil Oxalate, 	 Methysergide Maleate, Metiamide, Metiapine, Metioprim, 
Lofepramine Hydrochloride, lofetamine Hydrochloride 	 metipamide, Metipranolol, Metizoline Hydrochloride, Met- 
I-123, Lofexidine Hydrochloride, loglicic Acid, loglucol, 	 kephamid Acetate, metoclopramide, Metocurine Iodide, 
loglucomide, loglycamic Acid, logulamide, lohexyl, lombri- 	 Metogest, Metolazone, Metopimazine, Metoprine, Meto- 
cine, Lomefloxacin, lomerizine, lomethin I-125, Lometraline 25 prolol, Metoprolol tartrate, Metouizine, metrifonate, Metri- 
Hydrochloride, lometrexol, Lomofungin, Lomoxicam, 	 zamide, Metrizoate Sodium, Metronidazole, Meturedepa, 
Lomustine, Lonapalene, lonazolac, lonidamine, lopamidol, 	 Metyrapone, Metyrosine, Mexiletine Hydrochloride, 
lopanoic Acid, Loperamide Hydrochloride, lophendylate, 	 Mexrenoate Potassium, Mezlocillin, Mianserin Hydrochlo- 
Lopinavir, loprocemic Acid, lopronic Acid, lopydol, lopy- 	 ride, mibefradil, Mibefradil Dihydrochloride, Mibolerone, 
done, loracarbef, Lorajmine Hydrochloride, loratadine, 30 michellamine B, Miconazole, microcolinA, Midaflur, Mida- 
Lorazepam, Lorbamate, Lorcamide Hydrochloride, Lore- 	 zolam Hydrochloride, midodrine, mifepristone, Mifobate, 
clezole, Loreinadol, lorglumide, Lormetazepam, Lomoxi- 	 miglitol, milacemide, milameline, mildronate, Milenperone, 
cam, lornoxicam, Lortalamine, Lorzafone, losartan, Losartan 	 Milipertine, milnacipran, Milrinone, miltefosine, Mimbane 
potassium, losefamic Acid, loseric Acid, losigamone, losox- 	 Hydrochloride, minaprine, Minaxolone, Minocromil, 
antrone, losulamide Meglumine, Losulazine Hydrochloride, 35 Minocycline, Minocycline hydrochloride, Minoxidil, 
losumetic Acid, lotasul, loteprednol, lotetric Acid, lothala- 	 Mioflazine Hydrochloride, miokamycin, mipragoside, mir- 
mate Sodium, lothalamic Acid, lotrolan, lotroxic Acid, lov- 	 fentanil, mirimostim, Mirincamycin Hydrochloride, 
astatin, loversol, loviride, loxagiate Sodium, loxaglate 	 Mirisetron Maleate, Mirtazapine, Misonidazole, Misopros- 
Meglumine, loxaglic Acid, Loxapine, Loxoribine, loxotri- 	 tol, Mitindomide, Mitocarcin, Mitocromin, Mitogillin, 
zoic Acid, lubeluzole, Lucanthone Hydrochloride, Lufironil, 40 mitoguazone, mitolactol, Mitomalcin, Mitomycin, mitona- 
Lurosetron Mesylate, lurtotecan, lutetium, Lutrelin Acetate, 	 fide, Mitosper, Mitotane, mitoxantrone, mivacurium chlo- 
luzindole, Lyapolate Sodium, Lycetamine, lydicamycin, 	 ride, mivazerol, mixanpril, Mixidine, mizolastine, mizorib- 
Lydimycin, Lynestrenol, Lypressin, Lysine, lysofylline, lyso- 	 ine, Moclobemide, modafinil, Modaline Sulfate, 
staphin, Maduramicin, Mafenide, magainin 2 amide, Magne- 	 Modecamide, moexipril, mofarotene, Mofegiline Hydro- 
sium Salicylate, Magnesium Sulfate, magnolol, maitansine, 45 chloride, mofezolac, molgramostim, Molinazone, Molin- 
Malethamer, mallotoaponin, mallotochromene, Malotilate, 	 done Hydrochloride, Molsidomine, mometasone, Monatepil 
malotilate, mangafodipir, manidipine, maniwamycin A, 	 Maleate, Monensin, Monoctanoin, montelukast, Mon- 
Mannitol, mannostatin A, manumycin E, manumycin F, 	 telukast Sodium, montirelin, mopidamol, moracizine, Mor- 
mapinastine, Maprotiline, maraviroc, marimastat, Marinol, 	 antel Tartrate, Moricizine, Morniflumate, Morphine, Mor- 
Masoprocol, maspin, massetolide, Maytansine, Mazapertine 5o rhuate Sodium, mosapramine, mosapride, motilide, 
Succiniate, Mazindol, Mebendazole, Mebeverine Hydro- 	 Motretinide, Moxalactam Disodium, Moxazocine, Moxi- 
chloride, Mebrofenin, Mebutamate, Mecamylamine Hydro- 	 floxacin, moxiraprine, Moxnidazole, moxonidine, Mumps 
chloride, Mechlorethamine Hydrochloride, meclizine hydro- 	 Skin Test Antigen, Muzolimine, mycaperoxide B, Mycophe- 
chloride, 	 Meclocycline, 	 Meclofenamate 	 Sodium, 	 nolate mofetil, Mycophenolic Acid, myriaporone, Nabazenil, 
Mecloqualone, Meclorisone Dibutyrate, Medazepam Hydro-  55 Nabilone, Nabitan Hydrochloride, Naboctate Hydrochloride, 
chloride, Medorinone, Medrogestone, Medroxalol, Medrox- 	 Nabumetone, N-acetyldinaline, Nadide, nadifloxacin, Nad- 
yprogesterone, Medrysone, Meelizine Hydrochloride, Mefe- 	 olol, nadroparin calcium, nafadotride, nafamostat, nafarelin, 
namic Acid, Mefenidil, Mefenorex Hydrochloride, 	 Nafcillin Sodium, Nafenopin, Nafimidone Hydrochloride, 
Mefexamide, Mefloquine Hydrochloride, Mefruside, Mega- 	 Naflocort, Nafomine Malate, Nafoxidine Hydrochloride, 
lomicin Potassium Phosphate, Megestrol Acetate, Meglu-  6o Nafronyl Oxalate, Naftifine Hydrochloride, naftopidil, nagli- 
mine, Meglutol, Melengestrol Acetate, Meloxicam, Mel- 	 van, nagrestip, Nalbuphine Hydrochloride, Nalidixate 
phalan, Memantine, Memotine Hydrochloride, Menabitan 	 Sodium, Nalidixic Acid, nalmefene, Nalmexone Hydrochlo- 
Hydrochloride, Menoctone, menogaril, Menotropins, 	 ride, naloxone, Naltrexone, Namoxyrate, Nandrolone Phen- 
Meobentine Sulfate, Mepartricin, Mepenzolate Bromide, 	 propionate, Nantradol Hydrochloride, Napactadine Hydro- 
Meperidine Hydrochloride, Mephentermine Sulfate, Mephe-  65 chloride, napadisilate, Napamezole Hydrochloride, napaviin, 
nyloin, Mephobarbital, Mepivacaine Hydrochloride, Mep- 	 Naphazoline Hydrochloride, naphterpin, Naproxen, 
robamate, Meptazinol Hydrochloride, Mequidox, Meralein 	 Naproxen sodium, Naproxol, napsagatran, Naranol Hydro- 
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chloride, Narasin, naratriptan, nartograstim, nasaruplase, 
natalizumab, Natamycin, nateplase, Naxagolide Hydrochlo-
ride, Nebivolol, Nebramycin, nedaplatin, Nedocromil, Nefa-
zodone Hydrochloride, Neflumozide Hydrochloride, Nefo-
pam Hydrochloride, Nelezaprine Maleate, Nemazoline 
Hydrochloride, nemorubicin, Neomycin Palmitate, Neostig-
mine Bromide, neridronic acid, Netilmicin Sulfate, Neutra-
mycin, Nevirapin Nexeridine Hydrochloride, Niacin, 
Nibroxane, Nicardipine Hydrochloride, Nicergoline, 
Niclosamide, Nicorandil, Nicotinamide, Nicotinyl Alcohol, 
Nifedipine, Nifirmerone, Nifluridide, Nifuradene, Nifurald-
ezone, Nifuratel, Nifuratrone, Nifurdazil, Nifurimide, 
Nifurpirinol, Nifurquinazol, Nifurthiazole, Nifurtimox, nilo-
tinib, nilotinib hydrochloride monohydrate, nilutamide, Nil-
vadipine, Nimazone, Nimodipine, niperotidine, niravoline, 
Niridazole, nisamycin, Nisbuterol Mesylate, raisin, Nisobam-
ate, Nisoldipine, Nisoxetin Nisterime Acetate, Nitarsone, 
nitazoxanide, nitecapone, Nitrafudam Hydrochloride, 
Nitralamine Hydrochloride, Nitramisole Hydrochloride, 
Nitrazepam, Nitrendipine, Nitrocydine, Nitrodan, Nitro-
furantoin, Nitrofurazone, Nitroglycerin, Nitromersol, Nitro-
mide, Nitromifene Citrate, Nitrous Oxide, nitroxide antioxi-
dant, nitrullyn, Nivazol, Nivimedone Sodium, Nizatidine, 
Noberastine, Nocodazole, Nogalamycin, Nolinium Bromide, 
Nomifensine Maleate, Noracymethadol Hydrochloride, Nor-
bolethone, Norepinephrine Bitartrate, Norethindrone, Nor-
ethynodrel, Norfurane, Norfloxacin, Norgestimate, Norg-
estomet, Norgestrel, Nortriptyline Hydrochloride, 
Noscapine, Novobiocin Nylestriol, Nystatin, Obidoxime 
Chloride, Ocaperidone, Ocfentanil Hydrochloride, Ocina-
plon, Octanoic Acid, Octazamide, Octenidine Hydrochlo-
ride, Octodrine, Octreotide, Octriptyline Phosphate, Ofloxa-
cin, Ofornine, okicenone, Olanzepine, Olmesartan, 
olmesartan medoxomil, olopatadine, olopatadine hydrochlo-
ride, olprinone, olsalazine, Olsalazine Sodium, Olvanil, 
Omalizumab, Omega-3 acid ethyl esters, omeprazole, 
onapristone, ondansetron, Ontazolast, Oocyte Opipramol 
Hydrochloride, oracin, Orconazole Nitrate, Orgotein, Orlis-
lat, Ormaplatin, Onnetoprim, Ornidazole, Orpanoxin, 
Orphenadrine Citrate, osaterone, Oseltamivir, otenzepad, 
Oxacillin Sodium, Oxagrelate, oxaliplatin, Oxamarin Hydro-
chloride, oxamisole, Oxamniquine, oxandrolone, Oxantel 
Pamoate, Oxaprotiline Hydrochloride, Oxaprozin, Oxarba-
zole, Oxatomide, oxaunomycin, Oxazepam, oxcarbazepine, 
Oxendolone, Oxethazaine, Oxetorone Fumarate, Oxfenda-
zole, Oxfenicine, Oxibendazole, oxiconazole, Oxidopamine, 
Oxidronic Acid, Oxifungin Hydrochloride, Oxilorphan, Oxi-
monam, Oximonam Sodium, Oxiperomide, oxiracetam, 
Oxiramide, Oxisuran, Oxmetidine Hydrochloride, oxo-
dipine, Oxogestone Phenopropionate, Oxolinic Acid, Oxpre-
nolol Hydrochloride, Oxtriphylline, Oxybutynin Chloride, 
Oxychlorosene, Oxycodone, oxycodone hydrochloride, 
Oxymetazoline Hydrochloride, oxymetholone, Oxymor-
phone Hydrochloride, Oxypertine, Oxyphenbutazone, Oxy-
purinol, Oxytetracycline, Oxytocin, ozagrel, Ozlinone, Pacli-
taxel, palauamine, Paldimycin, palinavir, Palivizumab, 
palmitoylrhizoxin, Palmoxirate Sodium, pamaqueside, 
Pamatolol Sulfate, pamicogrel, Pamidronate Disodium, pam-
idronic acid, Panadiplon, panamesine, panaxytriol, Panco-
pride, Pancuronium Bromide, panipenem, pannorin, 
panomifene, pantethine, pantoprazole, Papaverine Hydro-
chloride, parabactin, paracetamol, Parachlorophenol, Paral-
dehyde, Paramethasone Acetate, Paranyline Hydrochloride, 
Parapenzolate Bromide, Pararosaniline Pamoate, Parbenda-
zole, Parconazole Hydrochloride, Paregoric, Pareptide Sul-
fate, Pargyline Hydrochloride, parnaparin sodium, Paromo-
mycin Sulfate, Paroxetine, paroxetine hydrochloride, 
parthenolide, Partricin, Paulomycin, pazelliptine, Pazina-
clone, Pazoxide, pazufloxacin, pefloxacin, pegaspargase, 
Pegorgotein, Pegylated interferon alfa-2a, Pelanserin Hydro-
chloride, peldesine, Peliomycipelretin, Pelrinone Hydrochlo- 
5 ride, Pemedolac, Pemerid Nitrate, Pemetrexed, pemirolast, 
Pemoline, Penamecillin, Penbutolol Sulfate, Penciclovir, 
Penfluridol, Penicillamine, Penicillin G Benzathine, Penicil-
lin G Potassium, Penicillin G Procaine, Penicillin G Sodium, 
Penicillin V Hydrabamine, Penicillin V Benzathine, Penicil- 
io lin V Potassium, Pentabamate, Pentaerythritol Tetranitrate, 
pentafuside, pentamidine, pentamorphone, Pentamustine, 
Pentapiperium Methylsulfate, Pentazocine, Pentetic Acid, 
Pentiapine Maleate, pentigetide, Pentisomicin, Pentizidone 
Sodium, Pentobarbital, Pentomone, Pentopril, pentosan, pen- 
15 tostatin, Pentoxifylline, Pentrinitrol, pentrozole, Peplomycin 
Sulfate, Pepstatin, perflubron, perfofamide, Perfosfamide, 
pergolide, Perhexyline Maleate, perillyl alcohol, Perindopril, 
perindoprilat, Perlapin Permethrin, perospirone, Perphena-
zine, Phenacemide, phenaridine, phenazinomycin, 
20 Phenazopyridine Hydrochloride, Phenbutazone Sodium 
Glycerate, Phencarbamide, Phencyclidine Hydrochloride, 
Phendimetrazine Tartrate, Phenelzine Sulfate, Phenformin, 
Phenmetrazine Hydrochloride, Phenobarbital, Phenoxyben-
zamine Hydrochloride, Phenprocoumon, phenserine, phen- 
25 succinal, Phensuximide, Phentermine, Phentermine Hydro-
chloride, phentolamine mesilate, Phentoxifylline, Phenyl 
Amino salicylate, phenylacetate, Phenylalanine, phenylala-
nylketoconazole, Phenylbutazone, Phenylephrine Hydro-
chloride, Phenylpropanolamine Hydrochloride, Phenylpro- 
30 panolamine Polistirex, Phenyramidol Hydrochloride, 
Phenyloin, Phenyloin sodium, Physostigmine, picenadol, 
picibanil, Picotrin Diolamine, picroliv, picumeterol, pidoti-
mod, Pifamine, Pilocarpine, pilsicamide, pimagedine, Pimet-
ine Hydrochloride, pimilprost, Pimobendan, Pimozide, Pina- 
35 cidil, Pinadoline, Pindolol, pinnenol, pinocebrin, Pinoxepin 
Hydrochloride, pioglitazone, Pipamperone, Pipazethate, 
pipecuronium bromide, Piperacetazine, Piperacillin, Piper-
acillin Sodium, Piperamide Maleate, piperazinc, Pipobro-
man, Piposulfan, Pipotiazine Palmitate, Pipoxolan Hydro- 
40 chloride, Piprozolin, Piquindone Hydrochloride, Piquizil 
Hydrochloride, Piracetam, Pirandamine Hydrochloride, pira-
rubicin, Pirazmonam Sodium, Pirazolac, Pirbenicillin 
Sodium, Pirbuterol Acetate, Pirenperone, Pirenzepine 
Hydrochloride, piretanide, Pirfenidone, Piridicillin Sodium, 
45 Piridronate Sodium, Piriprost, piritrexim, Pirlimycin Hydro-
chloride, pirlindole, pirmagrel, Pirmenol Hydrochloride, 
Pirnabine, Piroctone, Pirodavir, pirodomast, Pirogliride Tar-
trate, Pirolate, Pirolazamide, Piroxantrone Hydrochloride, 
Piroxicam, Piroximone, Pirprofen, Pirquinozol, Pirsidomine, 
50 Pivampicillin Hydrochloride, Pivopril, Pizotyline, placetinA, 
Plicamycin, Plomestane, Pobilukast Edamine, Podofilox, 
Poisonoak Extract, Poldine Methylsulfate, Poliglusam, 
Polignate Sodium, Polymyxin B Sulfate, Polythiazide, 
Ponalrestat, Porfimer Sodium, Porfiromycin, Potassium 
55 Chloride, Potassium Iodide, Potassium Permanganate, Povi-
done-Iodine, Practolol, Pralidoxime Chloride, Pramipexole, 
Pramiracetam Hydrochloride, Pramoxine Hydrochloride, 
Pranolium Chloride, Pravadoline Maleate, Pravastatin, Prav-
astatin sodium, Prazepam, Prazosin, Prazosin Hydrochloride, 
60 Prednazate, Prednicarbate, Prednimustine, Prednisolone, 
prednisolone quetiapine fumerate, Prednisone, Prednival, 
Pregabalin, Pregnenolone Succiniate, Prenalterol Hydrochlo-
ride, Prenylamine, Pridefine Hydrochloride, Prifelone, Prilo-
calne Hydrochloride, Prilosec, Primaquine Phosphate, Primi- 
65 dolol, Primidone, Prinivil, Prinomide Tromethamine, 
Prinoxodan, pritosufloxacin, Prizidilol Hydrochloride, 
Proadifen Hydrochloride, Probenecid, Probicromil Calcium, 
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Probucol, Procainamide Hydrochloride, Procaine Hydro-
chloride, Procarbazine Hydrochloride, Procaterol Hydro-
chloride, Prochlorperazine, Procinonide, Proclonol, Procy-
clidine Hydrochloride, Prodilidine Hydrochloride, Prodolic 
Acid, Profadol Hydrochloride, Progabide, Progesterone, Pro-
glumide, Proinsulin (human), Proline, Prolintane Hydrochlo-
ride, Promazine Hydrochloride, Promethazne, Promethaz-
ine hydrochloride, Propafenone Hydrochloride, 
propagermanium, Propanidid, Propantheline Bromide, Pro-
paracaine Hydrochloride, Propatyl Nitrate, propentofylline, 
Propenzolate Hydrochloride, Propikacin, Propiomazine, 
Propionic Acid, propionylcamitine, propiram, propiram, 
propiverine, Propofol, Proponolol hydrochloride, Pro-
poxycaine Hydrochloride, Propoxyphene Hydrochloride, 
Propranolol Hydrochloride, Propulsid, propylbis-acridone, 
Propylhexedrine, Propyliodone, Propylthiouracil, Proqua-
zone, Prorenoate Potassium, Proroxan Hydrochloride, 
Proscillaridin, Prostalene, prostratin, Protamine Sulfate, pro-
tegrin, Protirelin, Protriptyline Hydrochloride, Proxazole, 
Proxazole Citrate, Proxicromil, Proxorphan Tartrate, pruli-
floxacin, pseudoephedrine, Pseudophedrine hydrochloride, 
Puromycin, Pyrabrom, Pyrantel Pamoate, Pyrazinamide, 
Pyrazofurin, pyrazoloacridine, Pyridostigmine Bromide, 
Pyridoxine hydrochloride, Pyrilamine Maleate, 
Pyrimethamine, Pyrinoline, Pyrithione Sodium, Pyrithione 
Zinc, Pyrovalerone Hydrochloride, Pyroxamine Maleate, 
Pyrrocaine, Pyrroliphene Hydrochloride, PyrroInitrin, Pyrv-
inium Pamoate, Quadazocine Mesylate, Quazepam, Quazi-
none, Quazodine, Quazolast, quetiapine, quetiapine fuma-
rate, quiflapon, quinagolide, Quinaldine Blue, quinapril, 
Quinapril hydrochloride, Quinazosin Hydrochloride, Quin-
bolone, Quinctolate, Quindecamine Acetate, Quindonium 
Bromide, Quinelorane Hydrochloride, Quinestrol, Quinfa-
mide, Quingestanol Acetate, Quingestrone, Quinidine Glu-
conate, Quinelorane Hydrochloride, Quinine Sulfate, Quin-
pirole Hydrochloride, Quinterenol Sulfate, Quinuclium 
Bromide, Quinupristin, Quipazine Maleate, Rabeprazole, 
Rabeprazole Sodium, Racephencol, Racepinephrine, Rafox-
ande, Ralitoline, raloxifene, raltegravir, raltitrexed, rama-
troban, Ramipril, Ramoplann, ramosetron, ranelic acid, 
Ranmycin, Rantidine, Rantidine hydrochloride, ranola-
zine, Rauwolfia Serpentina, recainam, Recainam Hydrochlo-
ride, Reclazepam, Recombinant factor VIII, regavirumab, 
Regramostim, Relaxin, Relomycin, Remacemide Hydro-
chloride, Remifentanl Hydrochloride, Remiprostol, Remox-
ipride, Repirinast, Repromicin, Reproterol Hydrochloride, 
Reserpine, resinferatoxin, Resorcinol, retapamulin, retellip-
tine demethylated, reticulon, reviparin sodium, revizinone, 
rhenium etidronate, rhizoxin, RI retinamide, Ribaminol, Rib-
avirin, Riboprine, ricasetron, Ridogrel, Rifabutin, Rifamet-
ane, Rifamexil, Rifamide, Rifampin, Rifapentine, Rifaximin, 
rilopirox, Riluzole, rimantadine, Rimcazole Hydrochloride, 
Rimexolone, Rimiterol Hydrobromide, Rimonabant, rimo-
progin, riodipine, Rioprostil, Ripazepam, ripisartan, Risedr-
onate, Risedronate Sodium, risedronc acid, Risocaine, Riso-
tilide Hydrochloride, rispenzepine, Risperdal, Risperidone, 
Ritanserin, ritipenem, Ritodrine, Ritolukast, ritonavir, ritux-
imab, rivastigmine, rivastigmine tartrate, Rizatriptan, riza-
triptan benzoate, Rocastine Hydrochloride, Rocuronum 
Bromide, Rodocaine, Roflurane, Rogletimide, rohitukine, 
rokitamycin, Roletamicide, Rolgamidine, Rolicyprine, 
Rolipram, Rolitetracycline, Rolodine, Romazarit, romurtide, 
Rondazole, Ropinrole, Ropitoin Hydrochloride, ropiv-
acaine, Ropizine, roquinmex, Rosaramicin, rosiglitazone, 
Rosiglitazone maleate, Rosoxacin, Rosuvastatin, Rotavirus 
vaccine, rotigotine, Rotoxamine, roxaitidine, Roxarsone, 
roxindole, roxithromycin, rubiginone B1, ruboxyl, rufloxa- 
cin, rupatidine, Rutamycin, ruzadolane, Sabeluzole, safingol, 
safironil, saintopin, salbutamol, Salbutamol sulfate, Salcolex, 
Salethamide Maleate, Salicyl Alcohol, Salicylamide, Salicy-
lateMeglumine, Salicylic Acid, Salmeterol, Salnacediin, Sal- 
5 salate, sameridine, sampatrilat, Sancycline, sanfetrinem, 
Sanguinarium Chloride, Saperconazole, saprisartan, saprop-
terin, sapropterin dihydrochloride, saquinavir, Sarafloxacin 
Hydrochloride, Saralasin Acetate, sarcophytol A, sargra-
mostim, Sarmoxicillin, Sarpicillin, sarpogrelate, saruplase, 
io saterinone, satigrel, satumomab pendetide, Scopafungin, 
Scopolamine Hydrobromide, Scrazaipine Hydrochloride, 
Secalciferol, Secobarbital, Seelzone, segiline, Seglitide 
Acetate, Selegiline Hydrochloride, Selenium Sulfide, Sele-
nomethionine Se-75, Selfotel, sematilide, semduramicin, 
15 semotiadil, semustine, Sepazonium Chloride, Seperidol 
Hydrochloride, Seprilose, Seproxetine Hydrochloride, 
Seractide Acetate, Sergolexole Maleate, Serine, Sermetacin, 
Sermorelin Acetate, sertaconazole, sertindole, sertraline, ser-
traline hydrochloride, S-ethynyluracil, setiptiline, Setoper- 
20 one, Sevelamer, sevirumab, sevoflurane, sezolamide, 
Sibopirdine, Sibutramine Hydrochloride, Silandrone, 
Sildenafil, sildenafil citrate, silipide, silteplase, Silver Nitrate, 
simendan, Simtrazene, Simvastatin, Sincalide, Sinefungin, 
sinitrodil, sinnabidol, sipatrigine, sirolimus, Sisomicin, Sita- 
25 gliptin, Sitogluside, sizofuran, sobuzoxane, Sodium Amylo-
sulfate, Sodium Iodide I-123, Sodium Nitroprusside, Sodium 
Oxybate, sodium phenylacetate, Sodium Salicylate, Sodium 
valproate, Solifenacin, solverol, Solypertine Tartrate, Soma-
lapor, Somantadine Hydrochloride, somatomedin B, 
30 somatomedin C, Somatostatin, somatrem, somatropin, 
Somenopor, Somidobove, Sorbinil, Sorivudine, sotalol, 
Soterenol Hydrochloride, Sparfioxacin, Sparfosate Sodium, 
sparfosic acid, Sparsomy, Sparteine Sulfate, Spectinomycin 
Hydrochloride, spicamycin D, Spiperone, Spiradoline Mesy- 
35 late, Spiramycin, Spirapril Hydrochloride, Spiraprilat, 
Spirogermanum Hydrochloride, Spiromustine, Spironolac-
tone, Spiroplatin, Spiroxasone, splenopentin, spongistatin, 
Sprodiamide, squalamine, Stallimycin Hydrochloride, Stan-
nous Pyrophosphate, Stannous Sulfur Colloid, Stanozolol, 
40 Statolon, staurosporine, stavudine, Steffimycin, Stenbolone 
Acetate, stepronn, Stilbazium Iodide, Stilonum Iodide, 
stipiamide, Stiripentol, stobadine, Streptomycin Sulfate, 
Streptoncozid, Streptongrin, Streptozocin, Strontium Chlo-
ride Sr-89, succibun, Succimer, Succinylcholine Chloride, 
45 Sucralfate, Sucrosofate Potassium, Sudoxicam, Sufentanl, 
Sufotidine, Sulazepam, Sulbactam Pivoxil, Sulconazole 
Nitrate, Sulfabenz, Sulfabenzamide, Sulfacetamide, Sulfacy-
tine, Sulfadiazine, Sulfadoxine, Sulfalene, Sulfamerazine, 
Sulfameter, Sulfamethazine, Sulfamethizole, Sulfamethox- 
5o azole, Sulfamonomethoxine, Sulfamoxole, Sulfanlate Zinc, 
Sulfantran, sulfasalazine, Sulfasomizole, Sulfazamet, Sulfi-
nalol Hydrochloride, sulfinosine, Sulfinpyrazone, Sulfisox-
azole, Sulfomethoxazole, Sulfomyxin, Sulfonterol Hydro-
chloride, sulfoxamine, Sulinldac, Sulmarin, Sulndazole, 
55 Suloctidil, Sulofenur, sulopenem, Suloxifen Oxalate, 
Sulpiride, Sulprostone, sultamicillin, Sulthiame, sultopride, 
sulukast, Sumarotene, sumatriptan, Sumatriptan succinate, 
Suncillin Sodium, Suproclone, Suprofen, suradista, suramin, 
Surfomer, Suricamide Maleate, Suritozole, Suronacrine 
60 Maleate, Suxemerid Sulfate, swainsonne, symakalim, Sym-
closene, Symetine Hydrochloride, Taciamine Hydrochloride, 
Tacrine Hydrochloride, Tacrolimus, Tadalafil, Talampicillin 
Hydrochloride, Taleranol, Talisomycin, tallimustine, Tal-
metacin, Talnflumate, Talopram Hydrochloride, Talosalate, 
65 Tametraline Hydrochloride, Tamoxifen, tamoxifen citrate, 
Tampramine Fumarate, Tamsulosin, Tamsulosin Hydrochlo-
ride, Tandamine Hydrochloride, tandospirone, tapgen, tap- 
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rostene, Tasosartan, tauromustine, Taxane, Taxoid, Tazad-
olene Succinate, tazanolast, tazarotene, Tazifylline 
Hydrochloride, Tazobactam, Tazofelone, Tazolol Hydrochlo-
ride, Tebufelone, Tebuquine, Teclozan, Tecogalan Sodium, 
Teecleukin, Teflurane, Tegafur, Tegaserod, Tegretol, Teico-
planin, telenzepine, tellurapyrylium, telmesteine, telmisar-
tan, Teloxantrone Hydrochloride, Teludipine Hydrochloride, 
Temafloxacin Hydrochloride, Tematropium Methyl sulfate, 
Temazepam, Temelastine, temocapril, Temocillin, temopor-
fin, temozolomide, temsirolimus, Tenidap, Teniposide, Teno-
fovir, tenosal, tenoxicam, tepirindole, Tepoxalin, Teprotide, 
terazosin, Terazosin Hydrochloride, Terbinafine, Terbutaline 
Sulfate, Terconazole, terfenadine, terfiavoxate, terguride, 
Teriparatide, Teriparatide Acetate, terlakiren, terlipressin, 
terodiline, Teroxalene Hydrochloride, Teroxirone, tertatolol, 
Tesicam, Tesimide, Testolactone, Testosterone, Tetracaine, 
tetrachlorodecaoxide, Tetracycline, Tetracycline hydrochlo-
ride, Tetrahydrozoline Hydrochloride, Tetramisole Hydro-
chloride, Tetrazolast Meglumine, tetrazomine, Tetrofosmin, 
Tetroquinone, Tetroxoprim, Tetrydamine, thaliblastine, Tha-
lidomide, Theofibrate, Theophylline, Thiabendazole, Thia-
miprine, Thiamphenicol, Thiamylal, Thiazesim Hydrochlo-
ride, Thiazinamium Chloride, Thiethylperazine, Thiithixene, 
Thimerfonate Sodium, Thimerosal, thiocoraline, thiofedrine, 
Thioguanine, thiomarinol, Thiopental Sodium, thioperam-
ide, Thioridazine, Thiotepa, Thiphenamil Hydrochloride, 
Thiphencillin Potassium, Thiram, Thozalinone, Threoxine, 
Thrombin, thrombopoietin, thymalfasin, thymopentin, thy-
motrinan, Thyromedan Hydrochloride, Thyroxine, Tiacrilast, 
Tiacrilast Sodium, tiagabine, Tiamenidine, tianeptine, 
tiapafant, Tiapamil Hydrochloride, Tiaramide Hydrochlo-
ride, Tiazofurin, Tibenelast Sodium, Tibolone, Tibric Acid, 
Ticabesone Propionate, Ticarbodine, Ticarcillin Cresyl 
Sodium, Ticlatone, ticlopidine, Ticrynafen, tienoxolol, Tifu-
rac Sodium, Tigemonam Dicholine, Tigestol, Tiletamine 
Hydrochloride, Tilidine Hydrochloride, tilisolol, tilnoprofe-
narbamel, Tilorone Hydrochloride, Tiludronate Disodium, 
tiludronic acid, Timefurone, Timobesone Acetate, Timolol, 
Timolol meleate, Tinabinol, Timidazole, Tinzaparin Sodium, 
Tioconazole, Tiodazosin, Tiodonium Chloride, Tioperidone 
Hydrochloride, Tiopinac, Tiospirone Hydrochloride, Tioti-
dine, Tiotropium, tiotropium bromide, Tioxidazole, Tipen-
tosin Hydrochloride, tipranavir, Tipredane, Tiprenolol 
Hydrochloride, Tiprinast Meglumine, Tipropidil Hydrochlo-
ride, Tiqueside, Tiquinamide Hydrochloride, tirandalydigin, 
Tirapazamine, tirilazad, tirofiban, tiropramide, titanocene 
dichloride, Tixanox, Tixocortol Pivalate, Tizanidine Hydro-
chloride, Tnmethobenzamide Hydrochloride, Tobramycin, 
Tocamide, Tocamphyl, Tofenacin Hydrochloride, Tolamolol, 
Tolazamide, Tolazoline Hydrochloride, Tolbutamide, Tolca-
pone, Tolciclate, Tolfamide, Tolgabide, Tolimidone, Tolin-
date, Tolmetin, Tolnaftate, Tolpovidone, Tolpyrramide, Tolr-
estat, Tolterodine, tolterodine tartrate, Tomelukast, 
Tomoxetine Hydrochloride, Tonazocine Mesylate, Topira-
mate, topotecan, Topotecan Hydrochloride, topsentin, 
Topterone, Toquizine, torasemide, toremifene, Torsemide, 
Tosifen, Tosufloxacin, totipotent stem cell factor (TSCF), 
Tracazolate, trafermin, Tralonide, Tramadol, Tramadol 
Hydrochloride, Tramazoline Hydrochloride, trandolapril, 
Tranexamic Acid, Tranilast, Transcamide, trastuzumab, trax-
anox, Trazodone Hydrochloride, Trebenzomine Hydrochlo-
ride, Trefentanil Hydrochloride, Treloxinate, Trepipam 
Maleate, Trestolone Acetate, tretinoin, Triacetin, triacetylu-
ridine, Triafungin, Triamcinolone, Triampyzine Sulfate, Tri-
amterene, Triazolam, Tribenoside, tricaprilin, Tricetamide, 
Trichlonnethiazide, trichohyalin, triciribine, Tricitrates, Tri-
clofenol piperazine, Triclofos Sodium, trientine, Trifenagrel, 
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triflavin, Triflocin, Triflubazam, Triflumidate, Trifluopera-
zine Hydrochloride, Trifluperidol, Triflupromazine, Triflu-
promazine Hydrochloride, Trifluridine, Trihexyphenidyl 
Hydrochloride, Trilostane, Trimazosin Hydrochloride, tri- 
5 megestone, Trimeprazine Tartrate, Trimethadione, Tri-
methaphan Camsylate, Trimethoprim, Trimetozine, Trimetr-
exate, Trimipramine, Trimoprostil, Trimoxamine 
Hydrochloride, Triolein, Trioxifene Mesylate, Tripamide, 
Tripelennamine Hydrochloride, Triprolidine Hydrochloride, 
10 Triptorelin, Trisulfapyrimidines, Troclosene Potassium, tro-
glitazone, Trolamine, Troleandomycin, trombodipine, 
trometamol, Tropanserin Hydrochloride, Tropicamide, 
tropine, tropisetron, trospectomycin, trovafloxacin, trovird-
ine, Tryptophan, Tuberculin, Tubocurarine Chloride, Tubulo- 
15 zole Hydrochloride, tucaresol, tulobuterol, turosteride, 
Tybamate, tylogenin, Tyropanoate Sodium, Tyrosine, Tyro-
thricin, tyrphostins, ubenimex, Uldazepam, Undecylenic 
Acid, Uracil Mustard, urapidil, Urea, Uredepa, uridine triph-
osphate, Urofollitropin, Urokinase, Ursodiol, valaciclovir, 
20 Valacyclovir hydrochloride, Valine, Valnoctamide, Valproate 
semisodium, Valproic Acid, valsartan, vamicamide, vana-
deine, Vancomycin, vaminolol, Vapiprost Hydrochloride, 
Vapreotide, Vardenafil, Varenicline, variolin B, Vasopressin, 
Vecuronium Bromide, velaresol, Velnacrine Maleate, ven- 
25 lafaxine, Venlafaxine hydrochloride, Veradoline Hydrochlo-
ride, veramine, Verapamil Hydrochloride, verdins, Verilopam 
Hydrochloride, Verlukast, Verofylline, veroxan, verteporfin, 
Vesnarinone, vexibinol, Vidarabine, vigabatrin, vildagliptin, 
Viloxazine Hydrochloride, Vinblastine Sulfate, vinburnine 
30 citrate, Vincofos, vinconate, Vincristine Sulfate, Vindesine, 
Vindesine Sulfate, Vinepidine Sulfate, Vinglycinate Sulfate, 
Vinleurosine Sulfate, vinorelbine, vinpocetine, vintoperol, 
vinxaltine, Vinzolidine Sulfate, Viprostol, Virginiamycin, 
Viridofulvin, Viroxime, vitaxin, Voglibose, Volazocine, vori- 
35 conazole, vorozole, voxergolide, Wafarin, Xamoterol, 
Xanomeline, Xanoxate Sodium, Xanthinol Niacinate, 
xemiloflban, Xenalipin, Xenbucin, Xilobam, ximoprofen, 
Xipamide, Xorphanol Mesylate, Xylamidine Tosylate, Xyla-
zine Hydrochloride, Xylometazoline Hydrochloride, xylose, 
40 yangambin, zabicipril, zacopride, zafirlukast, Zalcitabine, 
Zaleplon, zalospirone, Zaltidine Hydrochloride, zaltoprofen, 
zanamivir, zankiren, zanoterone, Zantac, Zarirlukast, zate-
bradine, zatosetron, Zatosetron Maleate, zenarestat, Zenazo-
cine Mesylate, Zeniplatin, Zeranol, Zidometacin, Zidovu- 
45 dine, zifrosilone, Zilantel, zilascorb, zileuton, Zimeldine 
Hydrochloride, Zinc Undecylenate, Zindotrine, Zinocona-
zole Hydrochloride, Zinostatin, Zinterol Hydrochloride, Zin-
viroxime, ziprasidone, Zobolt, Zofenopril Calcium, Zofeno-
prilat, Zolamine Hydrochloride, Zolazepam Hydrochloride, 
50 Zoledronate, Zolertine Hydrochloride, zolmitriptan, zolpi-
dem, Zomepirac Sodium, Zometapine, Zoniclezole Hydro-
chloride, Zonisamide, zopiclone, Zopolrestat, Zorbamyciin, 
Zorubicin Hydrochloride, zotepine, Zucapsaicin, and phar-
maceutically acceptable salts thereof. 
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Example 1 
The capsule as described herein is used to administer leu-
prolide acetate for the treatment of prostate cancer. Leupro- 
60 lide acetate (USP 31) is a synthetic nonapeptide agonist ana-
log of luteinizing hormone-releasing factor (LNHR). The 
leuprolide acetate molecule is approximately 1209 Daltons in 
weight and two to three nanometers in size. It is soluble in 
aqueous media at a level of approximately 10 mg/mL. An 
65 existing method of administering leuprolide via extended 
release is disclosed in U.S. Pat. No. 5,728,396 filed Jan. 30, 
1997 and incorporated herein by reference. 
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The nanochannel delivery device chip is installed in a 
capsule as described herein and filled with a 5 mg/mL leu-
prolide acetate solution (NDC number 0703-4014-18) for use 
in the treatment of prostate cancer. The capsule is sized to 
approximately 2.8 mL, so that the filled capsule contains 
approximately 14 mg of leuprolide acetate. If stronger con-
centrations of leuprolide acetate solution are used, the capsule 
volume may be correspondingly reduced. The capsule is 
implanted subcutaneously in the inner portion of the upper 
arm or upper leg or in the abdomen. The capsule is implanted, 
with optional use of a tissue separator, through a small inci-
sion in a clinical outpatient procedure and removed two to 
three months later through a small incision. For implant and 
explant, a small amount of anesthetic is used, for example, a 
1% lidocaine injection at the site. 
The micro- and nano-channel sizes of the nanochannel 
delivery device are chosen (for example, according to the 
model described in [Grattoni, A. Ferrari, M., Liu, X. Quality 
control method for micro-nano-channels silicon devices. 
U.S. Patent Application No. 61/049,287 (April 2008)]), to 
provide a release rate of about 120 µg/day can be obtained for 
about 90 days in certain embodiments. 
In this example, the nanochannel delivery device configu-
ration with this behavior uses a 6x6 mm chip size, with 161 
macrochannels with openings of 190x190 µm each, and 
within each macrochannel approximately 23 rows of 
nanochannel structures, consisting of 10 each of inlet and 
outlet microchannels, connected through about 20 nanochan-
nels according to the description herein. The inlets and outlets 
are approximately 5x5 µm in cross-section, with the inlets 
being about 30 µm long and the outlets being about 1.6 µm 
long, and the nanochannels are about 5µm long and 5 µm 
wide and 13 mu high. Other configurations with different 
dimensions may be derived from the mathematical model that 
yield approximately the same release rate and duration in 
other examples. 
Example 2 
The capsule and nanochannel delivery device are config-
ured and implanted as described in Example 1. However, 
instead of administering leuprolide acetate, the capsule and 
nanochannel delivery device administer letrozole for the 
treatment of breast cancer. The limited success of chemo-
therapy for the treatment of breast cancer emphasizes the 
need of novel preventive strategies to minimize the cancer 
occurrence. Recent studies have highlighted that aromatase 
inhibitors are promising chemopreventive agents for breast 
cancer through inhibition of estrogen biosynthesis. In par-
ticular, research has suggested that letrozole is an ideal can-
didate for chemoprevention for women in high risk group 
such as BRCAI positive. However, the low efficacy and the 
side effects associated with the conventional systemic admin-
istration of letrozole are limiting factors for its long term 
usage. 
Breast cancer growth is highly dependent on estrogen, and 
thus inhibition of estrogen is highly effective for the preven-
tion of breast tumor development. Recent studies have high-
lighted aromatase inhibitors such as anastrozole, letrozole, 
and exemestane, as promising molecules that can be used for 
chemoprevention of breast cancer. Aromatase mediates bio-
synthesis of estradiol, the most potent form of estrogen, from 
androgens by the cytochrome P450 enzyme complex (Aro-
matase). Aromatase is present in breast tissue and the nonste-
roidal and steroidal aromatase inhibitors reduce circulating 
estrogen level to 1% to 10% of pretreatment levels, respec-
tively. Therefore, inhibition of aromatase is an important 
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approach for reducing growth-stimulatory effects of estro-
gens in estrogen-dependent breast cancer, which constitutes 
approximately 60-70% of breast cancer. Among the aro-
matase inhibitors, letrozole is a highly potent non-steroid 
5 inhibitor which inhibits approximately 99% of estrogen bio-
synthesis. Additionally, several studies and clinical trials on 
chemotherapy of metastatic breast cancer indicated higher 
efficacy with fewer side effects of letrozole when compared to 
Tamoxifen. Hence, research suggests letrozole as a candidate 
10 
for the development of chemopreventive therapy for women 
at increased risk of breast cancer. However, the conventional 
oral administration of letrozole showed increased risk of heart 
problems and osteoporosis. The key for the success of chemo-
prevention for breast cancer relies on long term delivery of 
specific drugs while circumventing side effects. As opposed 
15 to the inefficient oral administration, a constant local release 
of chemopreventive agent (i.e. letrozole) in breast tissue 
could significantly reduce occurrence of breast tumor as well 
as systemic side effects. This shows promise for improvement 
in patient quality of life. 
20 	 It is believed that the implantable nanochanneled devices 
according to the present disclosure will allow the constant and 
sustained local release of letrozole in breast tissues and sig-
nificant reduction of estrogen dependent epithelial cell pro-
liferation with minimum toxicities. 
25 	 Prior clinical trials employed letrozole daily doses of 2.5 
mg. It is believed that the constant local release of letrozole in 
breast tissues (utilizing nanochanneled devices according to 
the present disclosure) would require lower dosage if com-
pared to oral delivery. In first analysis it is believed that a local 
30 
daily release in the range 25 to 50 ug could be effective. 
The achievement of an efficient chemopreventive therapy 
by the use of long-term, constant release implants for local 
administration of chemopreventive agents will have signifi-
cant impact on the quality of life of women in the high risk 
group. It is believed that use of nanochannel delivery devices 
35 according to the present disclosure will lead to improved 
efficacy of therapy, as well as potential reduction of drug 
doses and reduction of side effects through true constant 
release. A reduction in the number of breast cancer occur-
rences due to effective preventive therapy would also have a 
40 positive economic impact on patients, their employers and 
insurers through lowered cost of treatment, fewer medical 
visits, and less work time lost. 
The development of a reliable extended release implant-
able technology adds a new dimension to drug delivery for 
45 breast cancer. Tumor treatment and the suppression of 
metastasis and/or tumor recurrence are natural follow-on 
developments. Technology enhancements to the initial plat-
form could support variable and programmed release, includ-
ing remote, interactive control of the implanted device, fur- 
50 
ther enabling capabilities to deploy multiple drugs 
simultaneously. In vivo refilling could also extend the func-
tionality of the nanochannel device and also decrease adverse 
events associated with explanation. As a general drug deliv-
ery method, other indications may be identified, broadening 
the applicability of the innovation. 
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Example 3 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
60 However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer lapatinib 
for the treatment of breast cancer. 
Example 4 
65 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
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However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer bupe-
norphine for the treatment of opiate dependency. 
Example 5 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer inter-
feron alpha implant for giant cell angioblastoma. 
Example 6 
The capsule and nanochannel delivery device are config-
ured and implanted in a patient as described in Example 1. 
However, instead of administering leuprolide acetate, the 
capsule and nanochannel delivery device administer zidovu-
dine in an intravaginal treatment for preventing HIV being 
transmitted from a pregnant mother to a child. 
As used herein, the term "direct fluid communication" is 
interpreted as fluid communication between two bodies that 
are directly connected, e.g. such that fluid may exit one body 
and immediately enter the second body without flowing 
through an intermediate body. For example, in the embodi-
ment shown in FIGS. 3A-3G, outlet 70 is in direct fluid 
communication with nanochannel 25. However, outlet 70 is 
not in direct fluid communication with inlet 30, because fluid 
must flow through an intermediate body (nanochannel 25) 
after exiting inlet 30 and before entering outlet 70. 
Furthermore, as used herein, the term "inlet" is interpreted 
as a chamber or reservoir within a nanochannel delivery 
device that initially retains a substance being delivered via the 
nanochannel delivery device. Similarly, an "outlet" is inter-
preted as a chamber or reservoir within a nanochannel deliv-
ery device that retains a substance immediately prior to the 
substance exiting the nanochannel delivery device. 
All of the devices, systems and/or methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
devices, systems and methods of this invention have been 
described in terms of particular embodiments, it will be 
apparent to those of skill in the art that variations may be 
applied to the devices, systems and/or methods in the steps or 
in the sequence of steps of the method described herein with-
out departing from the concept, spirit and scope of the inven-
tion. All such similar substitutes and modifications apparent 
to those skilled in the art are deemed to be within the spirit, 
scope and concept of the invention as defined by the appended 
claims. 
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The invention claimed is: 
1. A nanochannel delivery device comprising: 
a planar body comprising a first surface and a second 
30 	 surface opposing the first surface; 
an inlet microchannel; 
a nanochannel disposed within the planar body between 
the first surface and the second surface; and 
an outlet microchannel, wherein the inlet microchannel 
35 	 and the outlet microchannel are in direct fluid commu- 
nication with the nanochannel, wherein: 
the inlet microchannel extends from the nanochannel to 
the first surface; 
the outlet microchannel extends from the nanochannel 
40 	 to second the surface; and 
the nanochannel is oriented parallel to the primary plane 
of the nanochannel delivery device. 
2. The nanochannel delivery device of claim 1, wherein a 
flow path from the inlet microchannel to the nanochannel to 
45 the outlet microchannel requires a maximum of two changes 
in direction. 
3. The nanochannel delivery device of claim 1, wherein the 
inlet microchannel has a length, a width, and a depth; 
wherein the outlet microchannel has a length, a width, and 
50 	 a depth; 
wherein the nanochannel has a length, a width, and a depth; 
wherein the ratio of the nanochannel length to the inlet 
microchannel length is between 0.01 and 10.0; and 
wherein the ratio of the nanochannel length to the outlet 
55 	 microchannel length is between 0.01 and 10.0. 
4. The nanochannel delivery device of claim 3 wherein the 
ratio of the nanochannel length to either the inlet microchan-
nel length or the outlet microchannel length is between 0.2 
and 5.0. 
60 	 5. The nanochannel delivery device of claim 3 wherein the 
ratio of the nanochannel length to either the inlet microchan-
nel length or the outlet microchannel length is between 0.3 
and 3.0. 
6. The nanochannel delivery device of claim 3 wherein the 
65 ratio of the nanochannel length to either the inlet microchan-
nel length or the outlet microchannel length is between 0.4 
and 2.0. 
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7. The nanochannel delivery device of claim 3 wherein the 
ratio of the nanochannel length to either the inlet microchan-
nel length or the outlet microchannel length is between 0.5 
and 1.0. 
8. The nanochannel delivery device of claim 3 wherein the 
inlet microchannel is in direct fluid communication with the 
outlet microchannel via a single nanochannel. 
9. A nanochannel delivery device comprising: 
a planar body comprising a first surface and a second 
surface opposing the first surface; 
an inlet microchannel; 
nanochannel disposed within the planar body between the 
first surface and the second surface, wherein the 
nanochannel is oriented parallel to the primary plane of 
the nanochannel delivery device; 
an outlet microchannel, wherein the inlet microchannel 
extends from the nanochannel to the first surface and 
wherein the outlet microchannel extends from the 
nanochannel to the second surface; and 
a fluid flow path from the inlet microchannel to the outlet 
microchannel, wherein the fluid flow path requires a 
maximum of two changes in direction. 
10. A nanochannel delivery device comprising; 
a planar body comprising a first surface and a second 
surface opposing the first surface; 
a nanochannel disposed within the planar body between 
the first surface and the second surface; 
an inlet microchannel in fluid communication with the 
nanochannel; and 
an outlet microchannel in fluid communication with the 
nanochannel, wherein the inlet microchannel extends 
from the nanochannel to the first surface and wherein the 
outlet microchannel extends from the nanochannel to 
the second surface. 
11. A nanochannel delivery device comprising: 
a planar body comprising a first surface and a second 
surface opposing the first surface; 
a plurality of inlet microchannels; 
a plurality of nano channels disposed within the planar 
body between the first surface and the second surface; 
and 
a plurality of outlet microchannels, wherein each inlet 
microchannel is in direct fluid communication with an 
outlet microchannel via a single nanochannel, wherein 
the plurality of inlet microchannels extend to the first 
surface and wherein the plurality of outlet microchan-
nels extend to the second surface. 
12. A nanochannel delivery device comprising: 
a planar body including: 
a length, a width, and a thickness, wherein the length and 
the width are each greater than the thickness; 
an inlet surface on a first side of the planar body, wherein 
the inlet surface is bounded by the length and the width 
of the planar body; and 
an outlet surface on a second side of the planar body, 
wherein the outlet surface is bounded by the length and 
the width of the planar body, and wherein the inlet sur-
face is substantially parallel with the outlet surface; 
a nanochannel disposed within the planar body between 
the first surface and the second surface, wherein the 
nanochannel comprises an inlet end and an outlet end; 
50 
an inlet microchannel in fluid communication with the 
nanochannel; and 
an outlet microchannel in fluid communication with the 
nanochannel, wherein the inlet microchannel and 
5 nanochannel are configured such that a first linear axis 
can extend between the inlet surface and the inlet end of 
the nanochannel. 
13. An apparatus comprising the nanochannel delivery 
device of claim 1 inserted into a capsule. 
10 	 14. A nanochannel delivery device comprising: 
a planar body comprising a first surface and a second 
surface opposing the first surface; 
a plurality of inlet microchannels, wherein each of the inlet 
15 microchannels has a length, a width, and a depth, and 
wherein the inlet microchannel length is greater than the 
inlet microchannel width and depth; 
a plurality of outlet microchannels, wherein each of the 
outlet microchannels has a length, a width, and a depth; 
20 	 a plurality of nanochannels disposed within the planar 
body between the first surface and the second surface 
and in fluid communication with the plurality of inlet 
microchannels and outlet microchannels, wherein: 
the plurality of inlet microchannels extend to the first 
25 	 surface and wherein the plurality of outlet microchan- 
nels extend to the second surface; 
the plurality of inlet microchannels are arranged so that 
the inlet microchannel width and depth define a first 
plane that is parallel to the primary plane of the 
30 	
nanochannel delivery device; and 
the plurality of outlet microchannels are arranged so that 
the outlet microchannel width and depth define a sec-
ond plane that is parallel to the primary plane of the 
35 	 nanochannel delivery device. 
15. A method of treating a condition of a person, the 
method comprising: 
providing a nanochannel delivery device, wherein the 
nanochannel delivery device comprises: 
40 	 a planar body comprising a first surface and a second 
surface opposing the first surface; 
an inlet microchannel; 
a nanochannel disposed within the planar body between 
the first surface and the second surface; 
45 	 an outlet microchannel, wherein the inlet microchannel 
and the outlet microchannel are in fluid communica-
tion with the nanochannel; 
the inlet microchannel extends from the nanochannel to 
the first surface; 
50 	 the outlet microchannel extends from the nanochannel 
to second surface; and 
the nanochannel is oriented parallel to the primary plane 
of the nanochannel delivery device; 
55 	 providing a reservoir in fluid communication with the 
nanochannel delivery device; 
providing a substance in the reservoir, wherein the sub- 
stance is configured to treat the condition; and 
administering the substance to the person via the 
60 	 nanochannel delivery device. 
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